US5811151A - Method of modifying the surface of a medical device - Google Patents
Method of modifying the surface of a medical device Download PDFInfo
- Publication number
- US5811151A US5811151A US08/656,614 US65661496A US5811151A US 5811151 A US5811151 A US 5811151A US 65661496 A US65661496 A US 65661496A US 5811151 A US5811151 A US 5811151A
- Authority
- US
- United States
- Prior art keywords
- graft matrix
- surface graft
- matrix
- acid
- biomolecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/12—Polypeptides, proteins or derivatives thereof, e.g. degradation products thereof
- A61L33/128—Other specific proteins or polypeptides not covered by A61L33/122 - A61L33/126
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/044—Proteins; Polypeptides; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0029—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using an intermediate layer of polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0041—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate characterised by the choice of an antithrombatic agent other than heparin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0076—Chemical modification of the substrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0076—Chemical modification of the substrate
- A61L33/0088—Chemical modification of the substrate by grafting of a monomer onto the substrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
- Y10S530/816—Attached to the carrier via a bridging agent
Definitions
- the present invention relates to the field of medical devices. More particularly, the present invention relates to medical devices incorporating a biomolecule-coated surface graft matrix and methods of manufacturing the same.
- An alternative approach is to focus on the implant itself, and consequently on modification of the device to enhance infection-resistance by providing surfaces on the device that promote appropriate integration of the surrounding tissue(s) with the device surface.
- the underlying concept is that when rapid colonization and integration of the device surface with tissue cells is encouraged, the implant surface will be protected from bacterial colonization.
- One method of promoting tissue integration is through the use of collagen immobilized on the surface of the device because collagen materials promote a favorable tissue response. They provide a more physiological, isotropic environment that has been shown to promote the organization of different cell types into three-dimensional tissue-like structure. See, for example, Akita et al., Cell Tissue Res., 274, 91-95 (1993); and Berthod et al., Biomaterials, 14, 749-754 (1993). Implant studies have demonstrated that collagen-immobilization promotes favorable integration of tissue(s) with the implanted material. See, for example, Shimizu et al., Biomat., Med. Dev., Artif.
- One method of coating synthetic polymers with collagen involves a physical deposition of collagen, such that a laminar material results, as disclosed by Shimizu et al., Biomat., Med. Dev., Artif Org., 5, 49-66 (1977).
- One drawback to this method is that the collagen materials are prone to delamination in a moisture-abundant environment such as that typically experienced by implanted medical devices.
- Another method of providing a collagen-coated device involves covalently coupling collagen to a synthetic polymer substrate, as disclosed by Okada et al., Biomaterials and Clinical Applications, Elsevier Science Publishers B.V., Amsterdam, The Netherlands, pp. 465-470, 1987.
- the method includes graft copolymerization of acrylic acid, after which collagen is covalently coupled to the grafted poly(acrylic acid) chains, resulting in a blend-like matrix of collagen and poly(acrylic acid) chains.
- This construction is schematically depicted in FIG. 1, where the poly(acrylic acid) chains 12 are grafted to the surface 10 of a device.
- Collagen 14 is contained within the matrix formed by the chains 12.
- biological activity may be reduced as proper expression and accessibility are hampered.
- the present invention provides a medical device.
- the medical device comprises: a) a surface graft matrix comprising carboxyl-functional groups located on the device, the surface graft matrix comprising an outer portion; and b) one or more biomolecules covalently coupled to the surface graft matrix, wherein a majority of the biomolecules are located in the outer portion of the surface graft matrix.
- a medical device comprising: a) a surface graft matrix comprising carboxyl-functional groups located on the device, the surface graft matrix comprising an outer portion; b) one or more linker molecules covalently coupled to the surface graft matrix, wherein a majority of the linker molecules are located in the outer portion of the surface graft matrix; and c) one or more biomolecules covalently coupled to the linker molecules.
- the present invention also provides a method of modifying the surface of a medical device.
- the method comprises: (a) forming a surface graft matrix comprising carboxyl-functional groups on the surface of a medical device; (b) treating the surface graft matrix with an aqueous solution having a pH that is less than the pKa of the surface graft matrix; and (c) covalently coupling one or more biomolecules to the surface graft matrix in an aqueous solution having a pH that is less than the pKa of the surface graft matrix, wherein a majority of the biomolecules are located in the outer portion of the surface graft matrix.
- Also provided is a method of modifying the surface of a medical device comprising: (a) forming a surface graft matrix comprising carboxyl-functional groups on the surface of a medical device; (b) treating the surface graft matrix with an aqueous solution having a pH that is less than the pKa of the surface graft matrix; (c) covalently coupling one or more linker molecules to the surface graft matrix in an aqueous solution having a pH that is less than the pKa of the surface graft matrix, wherein a majority of the linker molecules are located in the outer portion of the surface graft matrix; and (d) covalently coupling one or more biomolecules to the linker molecules.
- the present invention also provides a method of delivering a pharmaceutical agent.
- the method comprises contacting a body with a medical device comprising a surface graft matrix comprising carboxyl-functional groups located on the device, the surface graft matrix comprising an outer portion in which a majority of one or more biomolecules are coupled, wherein the pharmaceutical agent is located within the surface graft matrix when the device is initially contacted with the body.
- FIG. 1 is a schematic cross-sectional diagram of a prior art surface graft matrix incorporating collagen.
- FIG. 2 is a schematic cross-sectional diagram of a surface graft matrix coated with a biomolecule sheath.
- FIG. 3 is a schematic cross-sectional diagram of a surface graft matrix coated with a biomolecule sheath, where the surface graft matrix is loaded with a pharmaceutical agent.
- FIG. 4 is a line drawing of the surface appearance of a surface graft matrix coated with collagen in a process according to the present invention.
- the present invention provides methods of covalently coupling a majority of one or more biomolecules in the outer portion of a surface graft matrix on a medical device.
- the surface graft matrix is preferably formed by surface grafting carboxyl-functional monomers, optionally in combination with vinyl monomers having no carboxyl functionality (COOH).
- COOH carboxyl functionality
- the surface graft matrix can result from the surface grafting of acrylic acid and acrylamide monomers, as disclosed in U.S. patent application Ser. No. 08/553,206, filed Nov. 7, 1995, entitled "Intramuscular Stimulation Lead With Enhanced Infection Resistance.”
- the surface graft matrix typically has an anionic character.
- a surface graft matrix that exhibits reduced permeability to medium-sized to large molecules is formed on the surface of a medical device, thereby providing the ability to isolate a majority of the subsequently coupled biomolecules to the outer portion of the surface graft matrix.
- the permeability of the surface graft matrix is reduced by treatment of the surface graft matrix at reduced pH levels, preferably where the pH of the solution is less than the pKa of the surface graft matrix.
- the surface graft matrix can be loaded with a pharmaceutical agent after the biomolecules are in place in the outer portion of the surface graft matrix.
- this loading occurs as a result of ionic interaction of the surface graft matrix with the pharmaceutical agent.
- a surface graft matrix exhibiting reduced permeability to medium-sized to large molecules is formed on the surface of a medical device.
- the permeability of the graft matrix is reduced by treatment of the surface graft matrix at reduced pH levels, preferably where the pH of the solution is less than the pKa of the surface graft matrix.
- linker molecules which may be biomolecules, referred to herein as intermediate biomolecules
- the relative impermeability of the graft matrix is maintained, restricting a majority of the linker molecules to the outer portion of the graft matrix.
- linker molecules e.g., intermediate biomolecules
- the linker molecules can then be used to covalently couple a majority of second biomolecules (referred to herein as primary biomolecules) in the outer portion of the surface graft matrix.
- This second coupling step is also preferably performed in solutions having pH values less than the pKa of the underlying surface graft matrix, thereby maintaining its relative impermeability to the biomolecules located in the outer portion of the surface graft matrix.
- the term "medical device” may be defined as a device that has surfaces that contact tissue, blood, or other bodily fluids in the course of their operation, which fluids are later used in patients. This can include, for example, extracorporeal devices for use in surgery such as blood oxygenators, blood pumps, blood sensors, tubing used to carry blood, and the like which contact blood that is returned to the patient.
- the term can also include endoprostheses implanted in blood contact in a human or animal body such as vascular grafts, stents, pacemaker leads, heart valves, and the like that are implanted in blood vessels or in the heart.
- the term can further include devices for temporary intravascular use such as catheters, guide wires, and the like that are placed in blood vessels or the heart for purposes of monitoring or repair.
- the term can also include nerve electrodes, muscle electrodes, implantable pulse generators, implantable drug pumps, and defibrillators.
- biomolecule includes any biocompatible and/or biologically active molecule (i.e., "primary biomolecule") or an intermediate biomolecule (linker molecule) to which one or more primary biomolecules can be coupled. Unless otherwise indicated, the term “biomolecule” as used herein will be understood to include both primary and intermediate biomolecules.
- biomolecule is collagen, a biocompatible molecule that exists in many types.
- Types of biomolecules that can be coupled to the surface graft matrix in accordance with the present invention include, but are not limited to, antithrombotic agents, antibacterial agents, anti-inflammatory agents, growth factors, cytokines, naturally occurring or synthetically prepared proteins, peptides, amino acids, and mixtures thereof.
- biomolecules that can be coupled to the surface graft matrix include, but are not limited to, albumin, fibrinogen, laminin, vitronectin, fibronectin, RGD-containing peptides, heparin, heparin sulfate, fibroblast growth factors (FGF), insulin-like growth factor, nerve growth factor, interferons (IFN), tumor necrosis factors (TNF), interleukins, gelatin, elastin, fibrin, von Willebrand factor, dermatan sulfate, hyaluronic acid, dextran sulfate, and mixtures thereof.
- FGF fibroblast growth factors
- IFN interferons
- TNF tumor necrosis factors
- biomolecules may be neutral or charged at the conditions employed during covalent coupling.
- biomolecules may be coupled to the surface graft matrix directly (i.e., through the carboxyl groups), or through well-known coupling chemistries, such as, for example, esterification, amidation, and acylation.
- These biomolecules are typically the primary biomolecules, although certain of them can be used as the intermediate biomolecules. It will be understood that the outer sheath of biomolecules typically includes a plurality of biomolecules, although it could include polymerized biomolecules that technically form one macromolecule.
- linker molecules which may or may not be biomolecules, in connection with the present invention typically involves covalently coupling a majority of the linker molecules in the outer portion of the surface graft matrix. After covalent coupling to the surface graft matrix, the linker molecules can provide the surface graft matrix with a number of functionally active groups that can be used to covalently couple one or more primary biomolecules.
- the linker molecules may be coupled to the surface graft matrix directly (i.e., through the carboxyl groups), or through well-known coupling chemistries, such as, for example, esterification, amidation, and acylation.
- the linker molecule is at least a di- or tri-amine functional compound that is coupled to the surface graft matrix through the direct formation of amide bonds, and provides amine-functional groups that are available for reaction with the primary biomolecule. More preferably, the linker molecule is a polyamine functional polymer such as polyethyleneimine (PEI) or polyallylamine (PALLA). Mixtures of these polymers can also be used. These molecules contain a plurality of pendant amine-functional groups that can be used to surface-immobilize one or more primary biomolecules.
- PEI polyethyleneimine
- PALLA polyallylamine
- FIG. 2 is a schematic cross-sectional view of a portion of the surface of a medical device 20, depicting that the biomolecules 24 are covalently coupled to a surface graft matrix 22 in a manner such that a majority of the biomolecules 24 are located or immobilized in the outer portion of the surface graft matrix 22 located on the medical device 20.
- the immobilization of the biomolecules 24 as depicted in FIG. 2 differs from the prior art depicted in FIG. 1 in that a majority of the biomolecules 24 are located on or near the outer surface of the surface graft matrix 22, not generally dispersed throughout the structure of the matrix as depicted in FIG. 1. This surface isolation of a majority of the biomolecules is advantageous because it allows a less disturbed expression of the biomolecules, so that biological activity is retained at a significantly higher level.
- the depth of the outer portion of the surface graft matrix in which a majority of the biomolecules are immobilized is primarily dependent on the type of biomolecule immobilized and the reaction conditions employed. Typically, a majority of the biomolecules will be immobilized in the surface graft matrix within a depth of about 10 nm or less. For example, if collagen is the biomolecule immobilized in the outer portion of the surface graft matrix, the depth at which a majority of the collagen molecules are immobilized is about 7 nm or less.
- the immobilization approach of the present invention may prohibit movement of the coupled biomolecules into the graft matrix. This will especially be the case with immobilization of anionic biomolecules, such as the anti-coagulant heparin which will be repelled by the underlying anionic surface graft matrix.
- the matrix can be loaded with a pharmaceutical agent for subsequent release to effect a desired response in the patient.
- the pharmaceutical agent capacity of the matrix can be increased as compared to those surface graft matrix materials that allow complete penetration of biomolecules. This provides yet another advantage of the present invention.
- Pharmaceutical agents that can be used in connection with the present invention include, but are not limited to, antimicrobial agents, antibacterial agents, anticoagulant agents, antithrombotic agents, platelet agents, and anti-inflammatory agents.
- Other useful pharmaceutical agents can include, but are not limited to, dyes which act as biological ligands, steroids, enzymes, catalysts, hormones, growth factors, drugs, vitamins, antibodies, antigens, nucleic acids, peptides, DNA & RNA segments, and mixtures thereof.
- these pharmaceutical agents are hydrophilic, positively charged compounds.
- a medical device 120 incorporating a biomolecule 124 on a surface graft matrix 122 loaded with a desired pharmaceutical agent 126
- duplicate biological activities can be provided to improve the in vivo performance of the medical device.
- the biomolecules 124 can be, for example, collagen which will interact with the surrounding tissue to provide a favorable tissue integration.
- specific desired body mechanisms may be activated, or, in the case of antimicrobials, a protective mode of action is exhibited during the initial vulnerable period before the medical device/tissue interface is stabilized and when random colonization by bacteria might occur.
- the surface exhibits "bi-biofunctional" characteristics, i.e., two biofunctional activities including: a) promoting rapid tissue integration into the surface of the device, and b) releasing a pharmaceutical agent, such as an antimicrobial agent to reduce the risk of infection around an implanted device.
- a pharmaceutical agent such as an antimicrobial agent
- Processes according to the present invention typically begin with the formation of a surface graft matrix on the surface of a medical device.
- the surface grafting method involves the covalent surface grafting of a polymer, preferably water soluble polymer, based on carboxyl-functional monomers, including, but not limited to, acrylic acid, methacrylic acid, itaconic acid, trans-cinnamic acid, crotonic acid, linoleic acid, linolenic acid, maleic acid, sorbic acid, and mixtures thereof onto a substrate material.
- the carboxyl-functional surface graft matrix also may be obtained through chemical modification of non-carboxyl-functional monomers.
- ceric ion initiation is a preferred method to graft monomers to substrate surfaces, other grafting techniques may be used as well.
- Known examples of other initiation methods include corona discharge, UV irradiation, ozonization and ionizing radiation (e.g., 60 Co, X-rays, high energy electrons, plasma gas discharge, etc.).
- the substrates that can be modified by the method of the present invention include metals such as titanium/titanium alloys, TiNi (shape memory/super elastic), aluminum oxide, platinum/platinum alloys, stainless steels, MP35N, elgiloy, haynes 25, stellite, pyrolytic carbon, silver or glassy carbon; polymers such as polyamides, polycarbonates, polyethers, polyesters, polyolefins including polyethylenes or polypropylenes, polystyrenes, polyurethanes, polyvinyl chlorides, polyvinylpyrrolidones, silicone elastomers, fluoropolymers, polyacrylates, polyisoprenes, polytetrafluoroethylenes, and rubber; minerals or ceramics such as hydroxapatite; human or animal protein or tissue such as bone, skin, teeth, collagen, laminin, elastin or fibrin; organic materials such as wood, cellulose, or compressed carbon; and other materials such as glass, or
- Substrates made using these materials can be coated or uncoated, and derivatized (e.g., modified to include reactive functional groups) or underivatized.
- the substrate is polyurethane, to which the carboxyl-functional surface graft matrix can be directly coupled without any preactivation of the substrate surface.
- the substrate is a biomaterial for use in a number of medical devices such as vascular grafts, aortic grafts, arterial, venous, or vascular tubing, vascular stents, dialysis membranes, tubing, or connectors, blood oxygenator tubing or membranes, ultrafiltration membranes, intra-aortic balloons, blood bags, catheters, sutures, soft or hard tissue prostheses, synthetic prostheses, prosthetic heart valves, tissue adhesives, cardiac pacemaker leads, artificial organs, endotracheal tubes, lenses for the eye such as contact or intraocular lenses, blood handling equipment, apheresis equipment, diagnostic and monitoring catheters and sensors, biosensors, dental devices, drug delivery systems, or bodily implants of any kind.
- medical devices such as vascular grafts, aortic grafts, arterial, venous, or vascular tubing, vascular stents, dialysis membranes, tubing, or connectors, blood oxygenator tubing or membranes, ultrafiltration
- a polymer surface graft of acrylic acid is one preferred embodiment to be used for subsequent covalent coupling of one or more biomolecules to enclose the surface graft matrix.
- the surface graft matrix is preferably formed by surface grafting of the monomers acrylic acid and acrylamide in ratios that allow for later manipulation of the graft matrix.
- sufficient acrylic acid (or other carboxylic-functional monomer) should be present so as not to interfere with the mechanism of reducing the permeability of the surface graft matrix to provide for immobilization of a majority of the biomolecules in the outer portion of the surface graft matrix.
- acrylic acid is used to prepare the surface graft matrix in an amount of about 20-100 wt %, based on the total weight of the monomers used to prepare the surface graft matrix. More preferably, acrylic acid is used in an amount of about 50-90 wt %, and most preferably, in an amount of about 65-75 wt %. These weight percentages are also applicable to other carboxyl-functional monomers.
- a low pH immersion process is used to produce the surface graft matrix with the desired impermeability to provide for immobilization of a majority of the biomolecules in the outer portion of the surface graft matrix.
- a low pH solution By immersing the surface graft matrix in a low pH solution, the formation of carboxylic acid dimers and intra-polymer crosslinking in the surface graft matrix is provided.
- the bond strength of acetic acid dimers is approximately equal to 55-60 kJ/mole, as disclosed by Potter, Jr., et al., J. Phys. Chem., 59, 250-254 (1955).
- intrapolymer crosslinking within a poly(carboxylic acid) graft matrix will be of significant strength.
- the formation of intrapolymer crosslinks is characterized by an obvious sticky feel of the surface grafted material. This sticky feel is generally indicative of the cohesive forces of the surface graft matrix.
- the intrapolymer crosslinking reduces the permeability/accessibility of medium-sized to large, even polycationic, compounds into the surface graft matrix.
- a subsequent process of covalently coupling a majority of biomolecules in the outer portion of the surface graft matrix is also carried out at a pH that is less than the pKa of the surface graft matrix. This results in immobilization of the biomolecules such that a surface layer of primarily biomolecules, i.e., a sheath, is formed that substantially encloses the surface graft matrix. This additionally allows for more complete loading of the surface graft matrix with a pharmaceutical agent for subsequent release in vivo. Although it is preferred that the immersion process and the biomolecule coupling process be carried out sequentially, they could be carried out simultaneously.
- the pKa value of the surface graft matrix can be determined through FT-IR analysis, according to the method of Azeez et al., J. Appl. Polym. Sci., 58, 1741-1749 (1995). Using this method, the pKa of a 100% acrylic acid graft matrix is 6.3, which is in accordance with the findings of 4.9-6.7 disclosed by Park et al., Pharm. Res., 4,457-464 (1987) on acrylic acid/acrylamide copolymer hydrogels.
- the pKa values are generally dependent on the ionic strength of the environment and the fraction of acrylic acid in the copolymer. Typically, an increase in ionic strength decreases the pKa, whereas an increase in acrylic acid fraction increases the pKa.
- the pH of the solutions in which the surface graft matrix is treated to reduce permeability and in which biomolecules are attached are typically no greater than about 5.5.
- the pH is no greater than about 5, and more preferably, no greater than about 4.5.
- the pH is at least about 2, and more preferably, at least about 3.
- the methods of the present invention preferably involve surface grafting of carboxyl-functional monomers through a covalent interaction to a substrate at an acidic pH, preferably at a pH of less than about 5.5; washing the substrate with the surface graft matrix thereon in an aqueous solution having a pH greater than the pKa of the surface graft matrix (typically at a neutral pH) to allow for the removal of free monomers, oligomers, or polymers; immersing the substrate with the surface graft matrix thereon in a solution having a pH that is less than the pKa of the surface graft matrix; and covalently coupling a majority of the biomolecules in the outer portion of the surface graft matrix in a solution having a pH that is less than the pKa of the surface graft matrix.
- Polyurethane (PU) film material was made from 2363-55D PELLETHANE resin (Dow Chemical, Midland, Mich., USA) by Medtronic Promeon (Minneapolis, Minn., USA).
- Ceric(IV)ammonium nitrate, nitric acid (65%), sodium phosphate monobasic monohydrate, sodium phosphate dibasic, sodium chloride, and sodium azide were all obtained from Merck-Schuchardt (Darmstadt, Germany).
- Acrylic acid, MES monohydrate, di-sodium tartrate, N-hydroxysuccimide (NHS), 3-ethyl-1-(diaminopropyl)-carbodiimide (EDC), and sodium hydrogencarbonate were obtained from Aldrich Chemie (Bomem, Belgium).
- Acrylamide 99+%; electrophoresis grade was obtained from Acros Chimica (Geel, Belgium).
- Collagen type I; from calf skin
- TNBS 2,4,6-trinitrobenzenesulfonic acid
- Coomassie Blue was obtained from Pierce Europe BV (Oud Beijerland, The Netherlands).
- Collagenase (EC 3.4.24.3; from Clostridium histolyticum; type IA, 550 units/mg solid), and Tris-HCl were obtained from Sigma Chemie (Bornem, Belgium); di-sodium tetraborate decahydrate from Sigma Chemie (Borneum, Belgium); Toluidine Blue O dye from Sigma Chemie; Ponceau S dye from Sigma Chemie; SDS from Sigma Chemie; and gentamicin sulfate from Sigma Chemie.
- Acrylic acid was purified by conventional distillation. All other reagents were of reagent grade or higher and used without further purification.
- XPS X-Ray Photoelectron Spectroscopy
- Time of Flight Secondary Ion Mass Spectometry (ToF-SIMS) spectra were acquired using a VG IX23S instrument based on the Poschenreider design and equipped with a pulsed liquid metal ion source. A 30 keV Ga + primary ion beam was used at an incident angle of 38° to the surface normal. The secondary ions were accelerated to 5 keV for the analysis by applying a sample bias. For each sample, both positive and negative secondary ion spectra were collected using a total primary ion dose that did not exceed 2 ⁇ 10 11 ions cm -2 for static SIMS, such that the analyzed surfaces were effectively undamaged as a result of the ToFSIMS studies.
- FEG-SEM tests were carried out on a JEOL JSM 6301-F Field-Emission-Gun SEM operated at 2 kV after the samples were sputter coated with gold (2-4 nm) using an Edwards 5150B Sputter Coater.
- Extruded PELLETHANE 55D polyurethane films were ultrasonically cleaned in isopropyl alcohol (IPA) for 15 minutes prior to ceric ion initiated surface grafting. Immediately after the IPA-cleaning samples were dried in a forced air oven at 50°-60° C. for approximately 5 minutes. FT-IR investigation has demonstrated that 15 minutes IPA-treatment is sufficient to remove any surface contamination that originates from processing aides, such as bis-stearamide waxes, that may interfere with the grafting process.
- processing aides such as bis-stearamide waxes
- an aqueous grafting solution was prepared that was composed of 40% by weight acrylic acid monomer concentration (100 wt % acrylic acid), 6 mM of ceric ammonium nitrate (CAN) and 0.06M nitric acid (HNO 3 ). Prior to grafting, the grafting solution was treated to remove excess air by exposure to reduced pressure (18 mm Hg ⁇ 5 mm Hg) for a maximum of 2 minutes.
- Grafted samples (10 ⁇ 1 cm strips) were prepared by placing the cleaned and dried samples in an appropriate volume (25-30 ml) of the grafting solution. Grafting was allowed to continue for 15-20 minutes at 30° C., while stirring the solution.
- the samples were rinsed in deionized (DI) water to stop the grafting process as well as to clean the surface graft matrix formed.
- DI deionized
- PBS phosphate buffered saline
- a 0.1M tartrate solution di-sodium tartrate
- XPS X-Ray Photoelectron Spectroscopy
- the carboxylic acid groups are mainly ionized. This is confirmed by the presence of sodium (Table 1) and the prevalence of the COOX chemical state (Table 2). In the ionized state, carboxylic acids will not be capable of forming the dimer, i.e., the group that is essential for physically crosslinking the graft matrix. In contrast, at pH ⁇ pKa the carboxylic acid groups are hydrogenated and thus capable of forming that dimer-group. The hydrogenated state is confirmed by the absence of sodium (Table 1) and the prevalence of the COOH chemical state (Table 2).
- the surface graft matrix can be made impermeable for medium-sized to large (even polycationic) molecules by formation of carboxylic acid dimers to induce physical crosslinking. This was confirmed in an experiment that studied the effect of pH on the amount of the (polycationic) antimicrobial drug gentamicin that could be (ionically) immobilized.
- the solutions were prepared as follows:
- the surface grafted samples were gentamicin loaded and the amount of gentamicin loaded was determined. The difference in the gentamicin content before and after sample immersion was determined and used as a measure for the amount of gentamicin loaded into the samples.
- the TNBS derivatization reaction was allowed to proceed for 25-30 minutes at room temperature, after which the absorbance at 415 nm was measured, while 595 nm was used as the reference wavelength (BioRad Model 3550, 96 wells microplate reader, Veenendaal, The Netherlands).
- a 0.1M tartrate solution di-sodium tartrate
- the samples were immersed in a buffered solution containing 0.5 mg/ml collagen (type I).
- the solution was buffered in the pH range 4.0-4.5 with 0.02M MES.
- the collagen immobilization reaction was continued for at least 20 hours.
- the collagen-immobilized samples were rinsed in DI water, an aqueous 0.15M NaCl solution in DI water, and DI water again. Samples were dried at ambient conditions by air exposure.
- TNBS-staining confirmed the presence of amine-functional groups.
- TNBS staining was performed by immersing a 4 mm disc in 1 ml of aqueous 4% by weight NaHCO 3 . To this solution 1 ml of aqueous 0.5% by weight TNBS was added, after which the reaction was allowed to continue for 2 hours at 40° C. Finally, the sample was extensively rinsed in DI water and allowed to dry. A similar surface grafted disc, but not used for collagen immobilization, was used as the control. The difference in dye uptake was obvious visually. Considering the surface modification chemistry, these groups could only be derived from immobilized collagen.
- Coomassie Blue protein dye also was used as a analytical tool to verify the presence of immobilized collagen in the outer portion of the surface graft matrix.
- Coomassie Blue staining was performed by immersing a 4 mm disc in 1 ml of Coomassie Blue for 30 minutes. Thereafter, the sample was extensively rinsed in DI water and allowed to dry. A similar surface grafted disc, but not used for collagen immobilization, was used as the control. The difference in dye uptake was obvious visually.
- the processed surfaces were examined by FEG-SEM (Field Emission Gun Scanning Electron Microscope) operated at 2 kV; prior to SEM-analysis surfaces were sputter-coated with gold (2-4 nm).
- FEG-SEM Field Emission Gun Scanning Electron Microscope
- the extruded 55D PELLETHANE polyurethane material is a flat material.
- the acrylic acid grafted material exhibits a permeable matrix-like structure. Subsequent immobilization of collagen seems to have covered this surface matrix with a superimposed surface-layer.
- the velvet-like appearance of this surface layer is depicted in FIG. 4.
- FT-IR spectroscopy Another analytical technique that was used to confirm the immobilization of collagen was FT-IR spectroscopy. This technique allows for analysis of the top 0.2-1 ⁇ m surface layer of processed samples. The FT-IR spectra of collagen raw material, acrylic acid grafted 55D, and collagen-immobilized samples were compared. The spectrum of the collagen-immobilized sample obviously contained features of both the acrylic acid graft and the collagen raw material. Most characteristic was the rise of the collagen-related peaks at approximately 1635 nm and 1660 nm. This confirmed the presence of collagen in the surface top layer.
- XPS demonstrated that the collagen was well coupled to the surface graft matrix.
- the immobilized collagen and collagen reference spectra were very similar, as is displayed in the tables above. This indicates that the surface portion (3 nm) primarily consists of collagen, confirming that surface model depicted in FIG. 2 is correct.
- the analysis depth can be varied, and thus more information could be obtained regarding the thickness of the collagen top layer.
- the surface composition as well as the derived chemical functionalities are displayed of collagen-immobilized samples as a function of the analysis depth.
- the outermost surface carbon is enriched in C--C, C--H and C--O(H) bonding.
- the nitrogen is enhanced in C--NH--C bonding and the oxygen is enriched in C--OH bonding.
- the described results of the above XPS study are in full agreement with the surface model depicted in FIG. 2.
- the study demonstrated the presence of a discrete collagen top layer of at least 70 ⁇ thickness. Since at a depth of 60 ⁇ the concentration of carboxyl functionality started to increase progressively, it is expected that with increasing depths the collagen layer will start to lose its integrity and will shift into a blend of collagen and the poly(acrylic acid) making up the surface graft matrix. At some depth in the surface graft matrix, it is expected that substantially no collagen will be found within the surface graft matrix.
- ToF-SIMS Time-of-Flight Secondary Ion Mass Spectrometry
- the results of the ToF-SIMS testing also confirmed the presence of a collagen top layer, as the sample spectra displayed a rich array of N-containing signals. In addition to nonspecific peptide/protein characteristics, the spectra exhibit rich arrays of N-containing signals which are more diagnostic of particular amino acid residues.
- the collagen top layer displayed an outermost surface chemistry which differs to that of the collagen reference. While N-containing species are clearly present, there appears to be a higher relative proportion of species containing C/H and C/H/O for the collagen coating compared to the collagen reference. This indicates either an incomplete collagen top layer or a very thin collagen top layer, or some reorientation of the collagen molecules due to the immobilization.
- Collagen-immobilized samples were prepared as previously described in Example 2 above (100 wt % acrylic acid monomer used to prepare the surface graft matrix). The in vivo performance was investigated and compared to that of acrylic acid grafted 55D (55D-AA) and plain 55D samples (55D) as discussed below.
- 55D-CC had a similar or thinner tissue capsule compared to 55D and 55D-AA. These results may indicate that 55D-CC promotes a faster wound healing response as a result from its biological interaction with the body's responses. It appears that fibrin formation at the surface of 55D-CC plays a major role, which indicates that 55D-CC may promote coagulation.
- linker molecules covalently coupled to both the surface graft matrix and the biomolecules.
- linker molecules include, e.g., the amine-functional polymers polyethyleneimine (PEI) or polyallylamine (PALLA). These compounds contain pendant amine-functional groups that can be used to surface-immobilize a majority of the biomolecules in the outer portion of a surface graft matrix.
- PEI was surface-immobilized to substantially enclose the surface graft matrix.
- the PEI was subsequently used to surface-immobilize the anti-coagulant drug heparin.
- a 0.05M tartrate solution di-sodium tartrate
- heparin coupling After heparin coupling, representative samples were stained with the cationic dye Toluidine Blue O (TB). The presence of heparin is denoted by a metachromatic shift from blue to violet. While the primary graft alone demonstrated a blueish, dark violet color after TB-exposure, the heparinized surface demonstrated an obvious shift to light violet. This shift in color suggests successful surface-coupling of heparin. PS-uptake obviously decreased as a consequence of the heparin-coupling; this confirms presence of heparin as well as coupling of heparin reduces the cationic nature of the surface.
- Toluidine Blue O Toluidine Blue O
- heparin-immobilized sample exhibited significant heparin concentrations at the graft surface.
- the gentamicin solution used for loading the surface grafted sample was analyzed to determine its gentamicin content before and after loading. This was done using a TNBS Assay in which the gentamnicin-containing solution was adjusted to pH 9 by addition of 0.1M borate, after which 25 ⁇ l 0.03M aqueous TNBS was added per ml of sample-solution. The difference in gentamicin content before and after sample immersion was determined and used as a measure for the amount of gentamicin loaded. The amount of gentamicin loaded was expressed as ⁇ g/cm 2 and is reported below in Table 12.
- the gentamicin loading suggests that a majority of the immobilized PEI can be found in the outer portion of the surface graft matrix, i.e., the PEI has formed a relatively thin outer sheath on the matrix. If the PEI was dispersed throughout the surface graft matrix, it would be expected to diminish the capacity of the surface graft matrix to load gentamicin, as it would neutralize much of the negative charge of the surface graft matrix due to penetration of the PEI molecules into the graft matrix.
- Gentamicin release was performed by immersion of gentamicin loaded samples in phosphate buffered saline (PBS, pH 7.4) at 37° C.; a volume-to-surface ratio of 1:1 (ml:cm 2 ) typically was used throughout the experiment. At desired time points, the samples were withdrawn from the solution and immersed in fresh PBS. Solution samples were analyzed for their gentamicin content by means of the TNBS Assay discussed above.
- PBS phosphate buffered saline
- Heparin coupling did not significantly influence the gentamicin release profile. After an initial burst, gentamicin progressively released until completion in an approximate 2 weeks.
Abstract
Description
TABLE 1 ______________________________________ Surface composition (in atom %) according to XPS. Sample carbon nitrogen oxygen sodium ______________________________________ AA-grafted 55D 69.2 1.5 24.7 4.6 (pH > pKa) AA-grafted 55D 71.1 0.4 28.5 -- (pH < pKa) ______________________________________
TABLE 2 ______________________________________ Carbon chemical states according to XPS (in %). COOX sample C--C C--N C--O (ionized) COOH ______________________________________ AA-grafted 55D 73.2 -- 9.4 14.9 2.5 (pH > pKa) AA-grafted 55D 69.6 -- 8.3 0.7 21.4 (pH < pKa) ______________________________________
TABLE 2A ______________________________________ pH Prepatation ______________________________________ 3 0.01 M di-sodium tartrate dihydrate + 1 N HCl 4 0.01 M di-sodium tartrate dihydrate + 1 N HCl 5 0.01 M MES monohydrate + 1 N NaOH 6 0.01 M MES monohydrate + 1 N NaOH 7 0.01 M MES monohydrate + 1 N NaOH 8 0.01 M di-sodium tetraborate decahydrate + 1 N HCl 9 0.01 M di-sodium tetraborate decahydrate + 1 N HCl ______________________________________
TABLE 4 ______________________________________ Surface composition (in atom %) according to XPS. Sample carbon oxygen nitrogen silicon ______________________________________ collage reference 69.1 17.5 11.7 1.8 collage 67.9 18.9 11.8 1.4 immobilized ______________________________________
TABLE 5 ______________________________________ Carbon chemical states derived from XPS analysis (in %). Functional collagen grouping collagen reference immobilized ______________________________________ C--C 47 48 C--N 23 24 C--O 12 11 N--C═O 13 17 O--C═O 5 -- ______________________________________
TABLE 6 ______________________________________ Oxygen chemical states derived from XPS analysis (in %). functional collagen grouping collagen reference immobilized ______________________________________ C═O 39 35 NH--C═O 38 38 C--OH 17 23 H.sub.2 O 6 4 ______________________________________
TABLE 7 ______________________________________ Nitrogen chemical states derived from XPS analysis (in %). functional collagen grouping collagen reference immobilized ______________________________________ NH--C═O 70 77 --C--NH--C-- 30 23 ______________________________________
TABLE 8 ______________________________________ Surface composition (in atom %) according to XPS. analysis TOA depth (Å) carbon nitrogen oxygen silicone ______________________________________ 15° 15 71.4 9.1 17.3 2.2 35° 30 67.9 11.8 18.9 1.4 90° 70 64.9 13.6 20.7 0.7 ______________________________________
TABLE 9 ______________________________________ Carbon chemical states derived from XPS analysis (in %). analysis depth (Å) C--C/C--H C--N C--O N--C═O O--C═O ______________________________________ 15 53 18 14 15 -- 30 48 24 11 17 -- 70 41 22 16 17 5 collagen reference 47 23 12 13 5 ______________________________________
TABLE 10 ______________________________________ Oxygen chemical states derived from XPS analysis (in %). analysis depth (Å) C═O NH--C═O C--OH H.sub.2 O ______________________________________ 15 21 36 36 6 30 35 38 23 4 70 38 37 21 4 collagen reference 39 38 17 6 ______________________________________
TABLE 11 ______________________________________ Nitrogen chemical states derived from XPS analysis (in %). analysis depth (Å) NH--C═O --C--NH--C-- ______________________________________ 15 77 23 30 77 23 70 92 8 collagen reference 70 30 ______________________________________
TABLE 12 ______________________________________ Gentamicin loading capacity (mg/cm.sup.2) of surface grafted, and surface grafted + heparanized 55D PELLETHANE; effect of graft matrix composition (n = 3). grafted sample grafted/heparanized sample (PU.sub.graft) sample (PU.sub.hep) ______________________________________ X.sub.AA = 1 113 ± 24 108 ± 14 X.sub.AA = 0.7 38 ± 7 24 ± 5 ______________________________________
TABLE 13 ______________________________________ Antibacterial activity testing of gentamicin-releasing materials; comparison between grafted, and grafted/heparinized surfaces (n = 2). zone-of-inhibition Sample (mm.sup.2) ______________________________________ grafted (PU.sub.graft) 0 grafted + gentamicin (PU.sub.GS) 363 ± 24 grafted/heparinized (PU.sub.hep) 0 grafted/heparinized + gentamicin (Pu.sub.hep/GS) 347 ± 47 Genta-neo-sensitab control 617 ± 63 ______________________________________
Claims (15)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/656,614 US5811151A (en) | 1996-05-31 | 1996-05-31 | Method of modifying the surface of a medical device |
US08/813,470 US5866113A (en) | 1996-05-31 | 1997-03-07 | Medical device with biomolecule-coated surface graft matrix |
DE69718377T DE69718377T2 (en) | 1996-05-31 | 1997-05-12 | Medical device with a surface tanned and coated with biomolecules |
EP97303222A EP0809997B1 (en) | 1996-05-31 | 1997-05-12 | Medical device with biomolecule-coated surface graft matrix |
JP9130612A JPH1052488A (en) | 1996-05-31 | 1997-05-21 | Medical device with biomolecule-coated surface-grafted matrix |
AU23619/97A AU713357B2 (en) | 1996-05-31 | 1997-05-26 | Medical device with biomolecule-coated surface graft matrix |
CA002206147A CA2206147A1 (en) | 1996-05-31 | 1997-05-26 | Medical device with biomolecule-coated surface graft matrix |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/656,614 US5811151A (en) | 1996-05-31 | 1996-05-31 | Method of modifying the surface of a medical device |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/813,470 Division US5866113A (en) | 1996-05-31 | 1997-03-07 | Medical device with biomolecule-coated surface graft matrix |
Publications (1)
Publication Number | Publication Date |
---|---|
US5811151A true US5811151A (en) | 1998-09-22 |
Family
ID=24633806
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/656,614 Expired - Lifetime US5811151A (en) | 1996-05-31 | 1996-05-31 | Method of modifying the surface of a medical device |
US08/813,470 Expired - Lifetime US5866113A (en) | 1996-05-31 | 1997-03-07 | Medical device with biomolecule-coated surface graft matrix |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/813,470 Expired - Lifetime US5866113A (en) | 1996-05-31 | 1997-03-07 | Medical device with biomolecule-coated surface graft matrix |
Country Status (6)
Country | Link |
---|---|
US (2) | US5811151A (en) |
EP (1) | EP0809997B1 (en) |
JP (1) | JPH1052488A (en) |
AU (1) | AU713357B2 (en) |
CA (1) | CA2206147A1 (en) |
DE (1) | DE69718377T2 (en) |
Cited By (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6010475A (en) * | 1996-09-19 | 2000-01-04 | Hospal Industrie | Apparatus for the treatment of blood by extracorporeal circulation and process of manufacture |
US6093686A (en) * | 1998-03-12 | 2000-07-25 | Menicon Co., Ltd. | Liquid for contact lenses |
US6146771A (en) | 1997-07-01 | 2000-11-14 | Terumo Cardiovascular Systems Corporation | Process for modifying surfaces using the reaction product of a water-insoluble polymer and a polyalkylene imine |
US6248811B1 (en) * | 1997-01-03 | 2001-06-19 | Huels Aktiengesellschaft | Bioactive surface coating |
US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
US6309660B1 (en) | 1999-07-28 | 2001-10-30 | Edwards Lifesciences Corp. | Universal biocompatible coating platform for medical devices |
US6328762B1 (en) | 1999-04-27 | 2001-12-11 | Sulzer Biologics, Inc. | Prosthetic grafts |
US6340465B1 (en) | 1999-04-12 | 2002-01-22 | Edwards Lifesciences Corp. | Lubricious coatings for medical devices |
US6379383B1 (en) | 1999-11-19 | 2002-04-30 | Advanced Bio Prosthetic Surfaces, Ltd. | Endoluminal device exhibiting improved endothelialization and method of manufacture thereof |
US6444217B1 (en) * | 2000-04-25 | 2002-09-03 | University Of Washington | Drug delivery devices, and methods of use |
US20020165600A1 (en) * | 1999-11-19 | 2002-11-07 | Advanced Bio Prosthetic Surfaces, Ltd. | Guidewires and thin film catheter-sheaths and method of making same |
US20030028246A1 (en) * | 1999-11-19 | 2003-02-06 | Palmaz Julio C. | Compliant implantable medical devices and methods of making same |
US6537310B1 (en) | 1999-11-19 | 2003-03-25 | Advanced Bio Prosthetic Surfaces, Ltd. | Endoluminal implantable devices and method of making same |
US20030083741A1 (en) * | 2001-10-26 | 2003-05-01 | Yi-Ren Woo | Valved prosthesis with porous substrate |
US6579539B2 (en) | 1999-12-22 | 2003-06-17 | C. R. Bard, Inc. | Dual mode antimicrobial compositions |
US6596401B1 (en) | 1998-11-10 | 2003-07-22 | C. R. Bard Inc. | Silane copolymer compositions containing active agents |
WO2003082156A1 (en) * | 2002-03-22 | 2003-10-09 | Clemson University | Vascular biomaterial devices and methods |
US6695865B2 (en) | 2000-03-20 | 2004-02-24 | Advanced Bio Prosthetic Surfaces, Ltd. | Embolic protection device |
US6726718B1 (en) * | 1999-12-13 | 2004-04-27 | St. Jude Medical, Inc. | Medical articles prepared for cell adhesion |
US6733513B2 (en) | 1999-11-04 | 2004-05-11 | Advanced Bioprosthetic Surfaces, Ltd. | Balloon catheter having metal balloon and method of making same |
US6764505B1 (en) | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
US6849085B2 (en) | 1999-11-19 | 2005-02-01 | Advanced Bio Prosthetic Surfaces, Ltd. | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and method of making same |
US20050131521A1 (en) * | 2000-05-12 | 2005-06-16 | Denes Marton | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and methods of making same |
US20050147735A1 (en) * | 2003-12-23 | 2005-07-07 | Lowery Michael D. | Lubricious, biocompatible coatings for medical devices |
US7169173B2 (en) | 2001-06-29 | 2007-01-30 | Advanced Cardiovascular Systems, Inc. | Composite stent with regioselective material and a method of forming the same |
US7169178B1 (en) | 2002-11-12 | 2007-01-30 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
US7195641B2 (en) | 1999-11-19 | 2007-03-27 | Advanced Bio Prosthetic Surfaces, Ltd. | Valvular prostheses having metal or pseudometallic construction and methods of manufacture |
US20070075016A1 (en) * | 2005-08-23 | 2007-04-05 | Biomet Manufacturing Corp. | Method and apparatus for collecting biological materials |
US20070208321A1 (en) * | 2005-08-23 | 2007-09-06 | Biomet Manufacturing Corp. | Method And Apparatus For Collecting Biological Materials |
US7300457B2 (en) | 1999-11-19 | 2007-11-27 | Advanced Bio Prosthetic Surfaces, Ltd. | Self-supporting metallic implantable grafts, compliant implantable medical devices and methods of making same |
US20080241349A1 (en) * | 2007-04-02 | 2008-10-02 | Ension, Inc. | Process for preparing a substrate coated with a biomolecule |
US20090098186A1 (en) * | 2007-10-01 | 2009-04-16 | Exogenesis Corporation | Method and system for coating a surface of a medical device with a therapeutic agent and drug eluting medical devices made thereby |
US7704274B2 (en) | 2002-09-26 | 2010-04-27 | Advanced Bio Prothestic Surfaces, Ltd. | Implantable graft and methods of making same |
US7736687B2 (en) | 2006-01-31 | 2010-06-15 | Advance Bio Prosthetic Surfaces, Ltd. | Methods of making medical devices |
US7771774B2 (en) | 2005-11-14 | 2010-08-10 | Biomet 3l, LLC | Deposition of discrete nanoparticles on an implant surface |
US7780860B2 (en) | 2002-05-24 | 2010-08-24 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US7806276B2 (en) | 2007-04-12 | 2010-10-05 | Hanuman, Llc | Buoy suspension fractionation system |
US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
US7837884B2 (en) | 2002-05-03 | 2010-11-23 | Hanuman, Llc | Methods and apparatus for isolating platelets from blood |
US7845499B2 (en) | 2002-05-24 | 2010-12-07 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US7862495B2 (en) | 2001-05-31 | 2011-01-04 | Advanced Cardiovascular Systems, Inc. | Radiation or drug delivery source with activity gradient to minimize edge effects |
US7867547B2 (en) | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
US7992725B2 (en) | 2002-05-03 | 2011-08-09 | Biomet Biologics, Llc | Buoy suspension fractionation system |
US8003156B2 (en) | 2006-05-04 | 2011-08-23 | Advanced Cardiovascular Systems, Inc. | Rotatable support elements for stents |
US8017237B2 (en) | 2006-06-23 | 2011-09-13 | Abbott Cardiovascular Systems, Inc. | Nanoshells on polymers |
US8048448B2 (en) | 2006-06-15 | 2011-11-01 | Abbott Cardiovascular Systems Inc. | Nanoshells for drug delivery |
US8048441B2 (en) | 2007-06-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Nanobead releasing medical devices |
US8053078B2 (en) | 2005-04-11 | 2011-11-08 | Abbott Medical Optics Inc. | Medical devices having soft, flexible lubricious coatings |
US8197879B2 (en) | 2003-09-30 | 2012-06-12 | Advanced Cardiovascular Systems, Inc. | Method for selectively coating surfaces of a stent |
WO2012088045A1 (en) | 2010-12-23 | 2012-06-28 | Medtronic, Inc. | Medical electrical lead having biological surface and methods of making and using same |
US8309162B2 (en) | 2008-01-28 | 2012-11-13 | Biomet 3I, Llc | Implant surface with increased hydrophilicity |
US8313954B2 (en) | 2009-04-03 | 2012-11-20 | Biomet Biologics, Llc | All-in-one means of separating blood components |
US8328024B2 (en) | 2007-04-12 | 2012-12-11 | Hanuman, Llc | Buoy suspension fractionation system |
US8337711B2 (en) | 2008-02-29 | 2012-12-25 | Biomet Biologics, Llc | System and process for separating a material |
US8458879B2 (en) | 2001-07-03 | 2013-06-11 | Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. | Method of fabricating an implantable medical device |
US8480227B2 (en) | 2010-07-30 | 2013-07-09 | Novartis Ag | Silicone hydrogel lenses with water-rich surfaces |
US8567609B2 (en) | 2006-05-25 | 2013-10-29 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US8591391B2 (en) | 2010-04-12 | 2013-11-26 | Biomet Biologics, Llc | Method and apparatus for separating a material |
US8603530B2 (en) | 2006-06-14 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
US8641418B2 (en) | 2010-03-29 | 2014-02-04 | Biomet 3I, Llc | Titanium nano-scale etching on an implant surface |
US8641754B2 (en) | 2000-11-07 | 2014-02-04 | Advanced Bio Prosthetic Surfaces, Ltd. a wholly owned subsidiary of Palmaz Scientific, Inc. | Endoluminal stent, self-supporting endoluminal graft and methods of making same |
US8783470B2 (en) | 2009-03-06 | 2014-07-22 | Biomet Biologics, Llc | Method and apparatus for producing autologous thrombin |
WO2015009431A1 (en) * | 2013-07-19 | 2015-01-22 | Rarecyte, Inc. | Solution and method for adhering suspension components to a substrate |
US9005700B2 (en) | 2011-10-12 | 2015-04-14 | Novartis Ag | Method for making UV-absorbing ophthalmic lenses |
US9011800B2 (en) | 2009-07-16 | 2015-04-21 | Biomet Biologics, Llc | Method and apparatus for separating biological materials |
US9119956B2 (en) | 2012-11-21 | 2015-09-01 | Cardiac Pacemakers, Inc. | Medical electrodes with layered coatings |
US9131995B2 (en) | 2012-03-20 | 2015-09-15 | Biomet 3I, Llc | Surface treatment for an implant surface |
US9180289B2 (en) | 2012-08-29 | 2015-11-10 | Cardiac Pacemakers, Inc. | Enhanced low friction coating for medical leads and methods of making |
WO2016089966A1 (en) * | 2014-12-02 | 2016-06-09 | Rarecyte, Inc. | Solution and method for adhering suspension components to a substrate |
US9556243B2 (en) | 2013-03-15 | 2017-01-31 | Biomet Biologies, LLC | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US9642956B2 (en) | 2012-08-27 | 2017-05-09 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US9693841B2 (en) | 2007-04-02 | 2017-07-04 | Ension, Inc. | Surface treated staples, sutures and dental floss and methods of manufacturing the same |
US9701728B2 (en) | 2008-02-27 | 2017-07-11 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
US9708087B2 (en) | 2013-12-17 | 2017-07-18 | Novartis Ag | Silicone hydrogel lens with a crosslinked hydrophilic coating |
US9897589B2 (en) | 2002-05-24 | 2018-02-20 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US20180344906A1 (en) * | 2015-03-31 | 2018-12-06 | Toray Industries, Inc. | Antithrombotic metallic material |
US10172730B2 (en) | 1999-11-19 | 2019-01-08 | Vactronix Scientific, Llc | Stents with metallic covers and methods of making same |
US10338408B2 (en) | 2012-12-17 | 2019-07-02 | Novartis Ag | Method for making improved UV-absorbing ophthalmic lenses |
US10449740B2 (en) | 2015-12-15 | 2019-10-22 | Novartis Ag | Method for applying stable coating on silicone hydrogel contact lenses |
US10576130B2 (en) | 2013-03-15 | 2020-03-03 | Biomet Manufacturing, Llc | Treatment of collagen defects using protein solutions |
US10830923B2 (en) | 2017-12-13 | 2020-11-10 | Alcon Inc. | Method for producing MPS-compatible water gradient contact lenses |
US11002884B2 (en) | 2014-08-26 | 2021-05-11 | Alcon Inc. | Method for applying stable coating on silicone hydrogel contact lenses |
US20210369923A1 (en) * | 2020-05-26 | 2021-12-02 | Sichuan University | Recombinant human collagen-based multifunctional stent coating and preparation method thereof |
Families Citing this family (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6063405A (en) * | 1995-09-29 | 2000-05-16 | L.A.M. Pharmaceuticals, Llc | Sustained release delivery system |
US6562781B1 (en) | 1995-11-30 | 2003-05-13 | Hamilton Civic Hospitals Research Development Inc. | Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
US6491965B1 (en) * | 1995-11-30 | 2002-12-10 | Hamilton Civic Hospitals Research Development, Inc. | Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
US7045585B2 (en) * | 1995-11-30 | 2006-05-16 | Hamilton Civic Hospital Research Development Inc. | Methods of coating a device using anti-thrombin heparin |
US6033719A (en) * | 1996-04-25 | 2000-03-07 | Medtronic, Inc. | Method for covalent attachment of biomolecules to surfaces of medical devices |
US6776792B1 (en) * | 1997-04-24 | 2004-08-17 | Advanced Cardiovascular Systems Inc. | Coated endovascular stent |
US6221425B1 (en) * | 1998-01-30 | 2001-04-24 | Advanced Cardiovascular Systems, Inc. | Lubricious hydrophilic coating for an intracorporeal medical device |
US6395019B2 (en) | 1998-02-09 | 2002-05-28 | Trivascular, Inc. | Endovascular graft |
US6258371B1 (en) * | 1998-04-03 | 2001-07-10 | Medtronic Inc | Method for making biocompatible medical article |
CA2350628A1 (en) * | 1998-11-12 | 2000-05-18 | Polymer Biosciences, Inc. | Hemostatic polymer useful for rapid blood coagulation and hemostasis |
US6159531A (en) * | 1999-08-30 | 2000-12-12 | Cardiovasc, Inc. | Coating having biological activity and medical implant having surface carrying the same and method |
US8187303B2 (en) | 2004-04-22 | 2012-05-29 | Gmedelaware 2 Llc | Anti-rotation fixation element for spinal prostheses |
US6673116B2 (en) * | 1999-10-22 | 2004-01-06 | Mark A. Reiley | Intramedullary guidance systems and methods for installing ankle replacement prostheses |
EP1854433B1 (en) * | 1999-10-22 | 2010-05-12 | FSI Acquisition Sub, LLC | Facet arthroplasty devices |
US8496712B2 (en) | 1999-10-22 | 2013-07-30 | Inbone Technologies, Inc. | Systems and methods for installing ankle replacement prostheses |
US7674293B2 (en) * | 2004-04-22 | 2010-03-09 | Facet Solutions, Inc. | Crossbar spinal prosthesis having a modular design and related implantation methods |
US7691145B2 (en) * | 1999-10-22 | 2010-04-06 | Facet Solutions, Inc. | Prostheses, systems and methods for replacement of natural facet joints with artificial facet joint surfaces |
US6974478B2 (en) * | 1999-10-22 | 2005-12-13 | Archus Orthopedics, Inc. | Prostheses, systems and methods for replacement of natural facet joints with artificial facet joint surfaces |
US6811567B2 (en) * | 1999-10-22 | 2004-11-02 | Archus Orthopedics Inc. | Facet arthroplasty devices and methods |
AU2118601A (en) * | 1999-10-22 | 2001-05-08 | Mark A. Reiley | Ankle replacement system |
US6291428B1 (en) | 1999-12-20 | 2001-09-18 | The Hospital For Special Surgery | Peptides which promote bone-forming cell attraction and adhesion |
US7604663B1 (en) | 1999-12-30 | 2009-10-20 | St. Jude Medical, Inc. | Medical devices with polymer/inorganic substrate composites |
EP1645248B8 (en) * | 2000-02-04 | 2010-06-16 | Warsaw Orthopedic, Inc. | Expandable interbody spinal fusion implant having pivotally attached blocker |
US6814756B1 (en) * | 2000-02-04 | 2004-11-09 | Gary K. Michelson | Expandable threaded arcuate interbody spinal fusion implant with lordotic configuration during insertion |
US6743253B2 (en) * | 2000-02-29 | 2004-06-01 | Biomod Surfaces | Polyurethane-sealed biocompatible device and method for its preparation |
US7163712B2 (en) | 2000-03-03 | 2007-01-16 | Duke University | Microstamping activated polymer surfaces |
US6444254B1 (en) * | 2000-03-03 | 2002-09-03 | Duke University | Microstamping activated polymer surfaces |
US6451050B1 (en) | 2000-04-28 | 2002-09-17 | Cardiovasc, Inc. | Stent graft and method |
US6520984B1 (en) | 2000-04-28 | 2003-02-18 | Cardiovasc, Inc. | Stent graft assembly and method |
US20030114918A1 (en) * | 2000-04-28 | 2003-06-19 | Garrison Michi E. | Stent graft assembly and method |
US20080177310A1 (en) * | 2000-10-20 | 2008-07-24 | Archus Orthopedics, Inc. | Facet arthroplasty devices and methods |
US6783793B1 (en) * | 2000-10-26 | 2004-08-31 | Advanced Cardiovascular Systems, Inc. | Selective coating of medical devices |
US8372139B2 (en) * | 2001-02-14 | 2013-02-12 | Advanced Bio Prosthetic Surfaces, Ltd. | In vivo sensor and method of making same |
US7083642B2 (en) * | 2000-12-22 | 2006-08-01 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
US6986772B2 (en) * | 2001-03-01 | 2006-01-17 | Michelson Gary K | Dynamic lordotic guard with movable extensions for creating an implantation space posteriorly in the lumbar spine |
EP1272130B1 (en) * | 2001-02-04 | 2004-11-17 | MICHELSON, Gary Karlin | Instrumentation for inserting and deploying an expandable interbody spinal fusion implant |
US6896680B2 (en) * | 2001-03-01 | 2005-05-24 | Gary K. Michelson | Arcuate dynamic lordotic guard with movable extensions for creating an implantation space posteriorly in the lumbar spine |
CA2434688A1 (en) | 2001-03-01 | 2002-09-12 | Gary Karlin Michelson | Dynamic lordotic guard with movable extensions for creating an implantation space posteriorly in the lumbar spine and method for use thereof |
US6660034B1 (en) * | 2001-04-30 | 2003-12-09 | Advanced Cardiovascular Systems, Inc. | Stent for increasing blood flow to ischemic tissues and a method of using the same |
US7186256B2 (en) * | 2001-06-04 | 2007-03-06 | Warsaw Orthopedic, Inc. | Dynamic, modular, single-lock anterior cervical plate system having assembleable and movable segments |
JP4286130B2 (en) | 2001-06-04 | 2009-06-24 | ウォーソー・オーソペディック・インコーポレーテッド | Anterior cervical plate system having a vertebral body engaging fixture and a connecting plate, and its installation method |
US7097645B2 (en) * | 2001-06-04 | 2006-08-29 | Sdgi Holdings, Inc. | Dynamic single-lock anterior cervical plate system having non-detachably fastened and moveable segments |
EP1404243A4 (en) * | 2001-06-04 | 2010-05-19 | Warsaw Orthopedic Inc | Dynamic anterior cervical plate system having moveable segments, instrumentation, and method for installation thereof |
US7044952B2 (en) * | 2001-06-06 | 2006-05-16 | Sdgi Holdings, Inc. | Dynamic multilock anterior cervical plate system having non-detachably fastened and moveable segments |
US7041105B2 (en) * | 2001-06-06 | 2006-05-09 | Sdgi Holdings, Inc. | Dynamic, modular, multilock anterior cervical plate system having detachably fastened assembleable and moveable segments |
US6787179B2 (en) * | 2001-06-29 | 2004-09-07 | Ethicon, Inc. | Sterilization of bioactive coatings |
WO2003008006A1 (en) * | 2001-07-19 | 2003-01-30 | Dempsey, Donald, J. | Bioactive surface for titanium implants |
ES2278952T3 (en) * | 2001-07-26 | 2007-08-16 | Avantec Vascular Corporation | DEVICES FOR MANAGING THERAPEUTIC AGENTS WITH VARIABLE LIBERATION PROFILE. |
US20030055493A1 (en) * | 2001-09-19 | 2003-03-20 | Erin Carpenter | Enhancement of stent radiopacity using anchors and tags |
NL1019316C2 (en) * | 2001-11-06 | 2003-05-07 | Tno | A vascular prosthesis. |
DE10295443B4 (en) * | 2001-11-23 | 2018-10-18 | Feg Textiltechnik Forschungs- Und Entwicklungsgesellschaft Mbh | Textile implant with surface modification, and corresponding method for surface modification |
EP1469865A4 (en) * | 2001-12-31 | 2010-04-14 | Crosslink D Inc | Hemostatic compositions and methods for controlling bleeding |
US20030161938A1 (en) * | 2002-02-22 | 2003-08-28 | Bo Johnson | Composition and method for coating medical devices |
US20030195610A1 (en) * | 2002-04-04 | 2003-10-16 | Herrmann Robert A. | Processes for producing polymer coatings through surface polymerization |
CA2448513A1 (en) * | 2002-06-29 | 2003-12-29 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Isoflavone concentrates, as well as methods for their production |
US8227411B2 (en) * | 2002-08-20 | 2012-07-24 | BioSurface Engineering Technologies, Incle | FGF growth factor analogs |
US7598224B2 (en) | 2002-08-20 | 2009-10-06 | Biosurface Engineering Technologies, Inc. | Dual chain synthetic heparin-binding growth factor analogs |
US7166574B2 (en) | 2002-08-20 | 2007-01-23 | Biosurface Engineering Technologies, Inc. | Synthetic heparin-binding growth factor analogs |
DE60300277T2 (en) | 2002-11-08 | 2006-01-12 | Howmedica Osteonics Corp. | Laser generated porous surface |
US20060147332A1 (en) | 2004-12-30 | 2006-07-06 | Howmedica Osteonics Corp. | Laser-produced porous structure |
US20040220534A1 (en) * | 2003-04-29 | 2004-11-04 | Martens Paul W. | Medical device with antimicrobial layer |
US20040230304A1 (en) * | 2003-05-14 | 2004-11-18 | Archus Orthopedics Inc. | Prostheses, tools and methods for replacement of natural facet joints with artifical facet joint surfaces |
US20040230201A1 (en) * | 2003-05-14 | 2004-11-18 | Archus Orthopedics Inc. | Prostheses, tools and methods for replacement of natural facet joints with artifical facet joint surfaces |
US7608104B2 (en) * | 2003-05-14 | 2009-10-27 | Archus Orthopedics, Inc. | Prostheses, tools and methods for replacement of natural facet joints with artifical facet joint surfaces |
DE10328816A1 (en) * | 2003-06-21 | 2005-01-05 | Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin | Implantable stimulation electrode with a coating to increase tissue compatibility |
US7074238B2 (en) * | 2003-07-08 | 2006-07-11 | Archus Orthopedics, Inc. | Prostheses, tools and methods for replacement of natural facet joints with artificial facet joint surfaces |
US20050131406A1 (en) * | 2003-12-15 | 2005-06-16 | Archus Orthopedics, Inc. | Polyaxial adjustment of facet joint prostheses |
US7414028B1 (en) | 2004-02-04 | 2008-08-19 | Biosurface Engineering Technologies, Inc. | Growth factor analogs |
US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
US20060024347A1 (en) * | 2004-02-10 | 2006-02-02 | Biosurface Engineering Technologies, Inc. | Bioactive peptide coatings |
US7528105B1 (en) | 2004-02-10 | 2009-05-05 | Biosurface Engineering Technologies | Heterodimeric chain synthetic heparin-binding growth factor analogs |
US7671012B2 (en) | 2004-02-10 | 2010-03-02 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
DE602005023714D1 (en) | 2004-02-20 | 2010-11-04 | Biosurface Eng Tech Inc | BONE MORPHOGENETIC PROTEIN-2 POSITIVE MODULATOR (BMP-2) |
CN100558415C (en) * | 2004-02-28 | 2009-11-11 | 汉莫堤克科技公司 | The biocompatible coating of medical surfaces, method and purposes |
US7406775B2 (en) * | 2004-04-22 | 2008-08-05 | Archus Orthopedics, Inc. | Implantable orthopedic device component selection instrument and methods |
US20080082171A1 (en) * | 2004-04-22 | 2008-04-03 | Kuiper Mark K | Crossbar spinal prosthesis having a modular design and systems for treating spinal pathologies |
US7051451B2 (en) * | 2004-04-22 | 2006-05-30 | Archus Orthopedics, Inc. | Facet joint prosthesis measurement and implant tools |
US20070093833A1 (en) * | 2004-05-03 | 2007-04-26 | Kuiper Mark K | Crossbar spinal prosthesis having a modular design and related implantation methods |
CA2576636A1 (en) * | 2004-08-18 | 2006-03-02 | Archus Orthopedics, Inc. | Adjacent level facet arthroplasty devices, spine stabilization systems, and methods |
US20060041311A1 (en) * | 2004-08-18 | 2006-02-23 | Mcleer Thomas J | Devices and methods for treating facet joints |
CA2579374A1 (en) | 2004-09-07 | 2006-03-30 | Archemix Corp. | Aptamers to von willebrand factor and their use as thrombotic disease therapeutics |
US7566701B2 (en) * | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
US20070066551A1 (en) * | 2004-09-07 | 2007-03-22 | Keefe Anthony D | Aptamer medicinal chemistry |
US20060079895A1 (en) * | 2004-09-30 | 2006-04-13 | Mcleer Thomas J | Methods and devices for improved bonding of devices to bone |
US20060085075A1 (en) * | 2004-10-04 | 2006-04-20 | Archus Orthopedics, Inc. | Polymeric joint complex and methods of use |
US8221461B2 (en) | 2004-10-25 | 2012-07-17 | Gmedelaware 2 Llc | Crossbar spinal prosthesis having a modular design and systems for treating spinal pathologies |
JP4570445B2 (en) * | 2004-11-04 | 2010-10-27 | 独立行政法人科学技術振興機構 | Method for producing an indwelling medical device having a hybrid complex on its surface |
US20060115514A1 (en) * | 2004-11-26 | 2006-06-01 | Stela Gengrinovitch | Chelating and binding chemicals to a medical implant, medical device formed, and therapeutic applications |
JP2008534063A (en) * | 2005-03-22 | 2008-08-28 | アーカス・オーソペディクス・インコーポレーテッド | Minimally invasive spinal recovery system, apparatus, method and kit |
US8496686B2 (en) | 2005-03-22 | 2013-07-30 | Gmedelaware 2 Llc | Minimally invasive spine restoration systems, devices, methods and kits |
US8257438B2 (en) * | 2005-04-12 | 2012-09-04 | Warsaw Orthopedic, Inc. | Methods and devices for preserving motion in an articulating prosthetic disc |
US7182783B2 (en) * | 2005-04-25 | 2007-02-27 | Sdgi Holdings, Inc. | Selectively expandable composite structures for spinal arthroplasty |
JP4613867B2 (en) * | 2005-05-26 | 2011-01-19 | ソニー株式会社 | Content processing apparatus, content processing method, and computer program |
DE102005032691A1 (en) * | 2005-07-06 | 2007-01-18 | Biotronik Vi Patent Ag | Medical implant (e.g. stent) has a peroxidase covalently attached to its surface |
US8728387B2 (en) | 2005-12-06 | 2014-05-20 | Howmedica Osteonics Corp. | Laser-produced porous surface |
WO2007126428A2 (en) * | 2005-12-20 | 2007-11-08 | Archus Orthopedics, Inc. | Arthroplasty revision system and method |
US8690957B2 (en) | 2005-12-21 | 2014-04-08 | Warsaw Orthopedic, Inc. | Bone graft composition, method and implant |
JP2009526862A (en) * | 2006-02-15 | 2009-07-23 | マサチューセッツ・インスティテュート・オブ・テクノロジー | Medical devices and coatings containing non-exudable antimicrobial peptides |
WO2007106573A2 (en) * | 2006-03-15 | 2007-09-20 | Archus Orthopedics, Inc. | Facet and disc arthroplasty systems and methods |
US20070248653A1 (en) * | 2006-04-20 | 2007-10-25 | Cochrum Kent C | Hemostatic compositions and methods for controlling bleeding |
US20070254002A1 (en) * | 2006-04-26 | 2007-11-01 | Sheng-Qian Wu | Biocompatible devices coated with activated protein C |
US7820172B1 (en) | 2006-06-01 | 2010-10-26 | Biosurface Engineering Technologies, Inc. | Laminin-derived multi-domain peptides |
US20070288021A1 (en) * | 2006-06-07 | 2007-12-13 | Howmedica Osteonics Corp. | Flexible joint implant |
JP2009541358A (en) | 2006-06-22 | 2009-11-26 | バイオサーフェス エンジニアリング テクノロジーズ,インク. | Compositions and methods for delivering a BMP-2 amplification factor / co-activator to enhance bone formation |
WO2008019397A2 (en) * | 2006-08-11 | 2008-02-14 | Archus Orthopedics, Inc. | Angled washer polyaxial connection for dynamic spine prosthesis |
US20080188936A1 (en) * | 2007-02-02 | 2008-08-07 | Tornier, Inc. | System and method for repairing tendons and ligaments |
TW200840554A (en) * | 2007-02-28 | 2008-10-16 | Alcon Inc | Coated medical implants and lenses |
WO2008150495A2 (en) * | 2007-06-01 | 2008-12-11 | Archemix Corp. | Vwf aptamer formulations and methods for use |
US8133553B2 (en) | 2007-06-18 | 2012-03-13 | Zimmer, Inc. | Process for forming a ceramic layer |
US8309521B2 (en) | 2007-06-19 | 2012-11-13 | Zimmer, Inc. | Spacer with a coating thereon for use with an implant device |
WO2009014718A1 (en) | 2007-07-24 | 2009-01-29 | Porex Corporation | Porous laser sintered articles |
WO2009023276A1 (en) * | 2007-08-15 | 2009-02-19 | The Board Of Trustees Of The Leland Stanford Junior University | Sequential coupling of biomolecule layers to polymers |
US9247973B2 (en) * | 2007-09-28 | 2016-02-02 | DePuy Synthes Products, Inc. | Anti-microbial implant |
US20110230973A1 (en) * | 2007-10-10 | 2011-09-22 | Zimmer, Inc. | Method for bonding a tantalum structure to a cobalt-alloy substrate |
US8608049B2 (en) * | 2007-10-10 | 2013-12-17 | Zimmer, Inc. | Method for bonding a tantalum structure to a cobalt-alloy substrate |
TWI391485B (en) * | 2007-10-31 | 2013-04-01 | Forward Electronics Co Ltd | Method for biomolecule immobilization |
US20090155335A1 (en) * | 2007-12-05 | 2009-06-18 | Semprus Biosciences Corp. | Non-leaching non-fouling antimicrobial coatings |
WO2009075788A1 (en) * | 2007-12-05 | 2009-06-18 | Semprus Biociences Corporation | Synthetic non-fouling amino acids |
US20090187256A1 (en) * | 2008-01-21 | 2009-07-23 | Zimmer, Inc. | Method for forming an integral porous region in a cast implant |
US20090198286A1 (en) * | 2008-02-05 | 2009-08-06 | Zimmer, Inc. | Bone fracture fixation system |
US9095569B2 (en) | 2008-04-18 | 2015-08-04 | Collplant Ltd. | Methods of generating and using procollagen |
EP3045123B1 (en) | 2008-06-16 | 2020-04-08 | University Of Rochester | Compositions comprising a combination of fibroblast growth factor (fgf) analogs with thrombopoietin for use for treating acute radiation syndrome |
DE102008040787A1 (en) * | 2008-07-28 | 2010-02-04 | Biotronik Vi Patent Ag | Biocorrodible implant with a coating containing a hydrogel |
DE102008040786A1 (en) * | 2008-07-28 | 2010-02-04 | Biotronik Vi Patent Ag | Biocorrodible implant with a coating containing a drug-carrying polymer matrix |
CN102203173B (en) | 2008-09-19 | 2014-04-02 | 3M创新有限公司 | Ligand graft functionalized substrates |
WO2010065958A1 (en) | 2008-12-05 | 2010-06-10 | Semprus Biosciences Corp. | Layered non-fouling, antimicrobial, antithrombogenic coatings |
BRPI0922266A2 (en) * | 2008-12-05 | 2019-09-24 | Semprus Biosciences Corp | antithrombogenic, antimicrobial, antifouling graft compositions |
JP5464424B2 (en) * | 2010-01-15 | 2014-04-09 | 国立大学法人信州大学 | Flameproof fiber, flameproof fiber product, flameproof film, and method for producing the same |
WO2011156603A2 (en) | 2010-06-09 | 2011-12-15 | Semprus Biosciences Corp. | Articles having non-fouling surfaces and processes for preparing the same without altering bulk physical properties |
EP2579908A4 (en) | 2010-06-09 | 2016-03-23 | Arrow Int Inc | Non-fouling, anti-microbial, anti-thrombogenic graft-from compositions |
CA2799786A1 (en) | 2010-06-09 | 2011-12-15 | Semprus Biosciences Corp. | Non-fouling, anti-microbial, anti-thrombogenic graft compositions |
EP2535062A1 (en) * | 2011-06-13 | 2012-12-19 | Dentsply IH AB | Collagen coated article |
WO2012173555A1 (en) | 2011-06-13 | 2012-12-20 | Dentsply Ih Ab | Collagen coated article |
MX2014007202A (en) | 2011-12-14 | 2015-03-09 | Semprus Biosciences Corp | Surface modified contact lenses. |
MX2014007204A (en) | 2011-12-14 | 2015-04-14 | Semprus Biosciences Corp | Multistep uv process to create surface modified contact lenses. |
JP2015502437A (en) | 2011-12-14 | 2015-01-22 | センプラス・バイオサイエンシーズ・コーポレイションSemprus Biosciences Corp. | Silicone hydrogel contact lenses modified with lanthanides or transition metal oxidants |
EP2791214A4 (en) | 2011-12-14 | 2015-11-04 | Semprus Biosciences Corp | Redox processes for contact lens modification |
US9006359B2 (en) | 2011-12-14 | 2015-04-14 | Semprus Biosciences Corporation | Imbibing process for contact lens surface modification |
US9364896B2 (en) | 2012-02-07 | 2016-06-14 | Medical Modeling Inc. | Fabrication of hybrid solid-porous medical implantable devices with electron beam melting technology |
US9135374B2 (en) | 2012-04-06 | 2015-09-15 | Howmedica Osteonics Corp. | Surface modified unit cell lattice structures for optimized secure freeform fabrication |
US9180010B2 (en) | 2012-04-06 | 2015-11-10 | Howmedica Osteonics Corp. | Surface modified unit cell lattice structures for optimized secure freeform fabrication |
US9320592B2 (en) | 2013-03-15 | 2016-04-26 | Covidien Lp | Coated medical devices and methods of making and using same |
US9545301B2 (en) | 2013-03-15 | 2017-01-17 | Covidien Lp | Coated medical devices and methods of making and using same |
US9668890B2 (en) | 2013-11-22 | 2017-06-06 | Covidien Lp | Anti-thrombogenic medical devices and methods |
CA2928629C (en) * | 2013-11-28 | 2018-04-17 | Toray Industries, Inc. | Antithrombotic material |
CA2948613A1 (en) * | 2014-05-09 | 2015-11-12 | Dci Donor Services, Inc. | Tissue graft storage solutions and systems |
EP2985043A1 (en) * | 2014-08-14 | 2016-02-17 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Process for manufacturing a customizable medical device and device obtained by said process |
US9789228B2 (en) | 2014-12-11 | 2017-10-17 | Covidien Lp | Antimicrobial coatings for medical devices and processes for preparing such coatings |
US20180296737A1 (en) * | 2017-03-29 | 2018-10-18 | Covalon Technologies Ltd. | Coating compositions, polymeric coatings, and methods |
KR102101936B1 (en) * | 2017-10-19 | 2020-04-17 | 서울대학교병원 | Composition for suface modification of medical implants and suface modified medical implants using the same |
WO2024006522A1 (en) * | 2022-07-01 | 2024-01-04 | New York University | Synthetic supracrestal dental implant fibers |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229172A (en) * | 1993-01-19 | 1993-07-20 | Medtronic, Inc. | Modification of polymeric surface by graft polymerization |
US5308641A (en) * | 1993-01-19 | 1994-05-03 | Medtronic, Inc. | Biocompatibility of solid surfaces |
US5344455A (en) * | 1992-10-30 | 1994-09-06 | Medtronic, Inc. | Graft polymer articles having bioactive surfaces |
US5350800A (en) * | 1993-01-19 | 1994-09-27 | Medtronic, Inc. | Method for improving the biocompatibility of solid surfaces |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8701337A (en) * | 1987-06-09 | 1989-01-02 | Sentron V O F | SUBSTRATE PROVIDED WITH A BLOOD COMPATIBLE SURFACE OBTAINED BY COUPLING WITH THE SURFACE OF A PHYSIOLOGICALLY ACTIVE SUBSTANCE WITH AN INHIBITORY INFLUENCE ON THE FORMATION OF BLOOD CLOTS AND / OR CONTAINED FROM HARMFOLIC CIRCULARS. |
US5080924A (en) * | 1989-04-24 | 1992-01-14 | Drexel University | Method of making biocompatible, surface modified materials |
-
1996
- 1996-05-31 US US08/656,614 patent/US5811151A/en not_active Expired - Lifetime
-
1997
- 1997-03-07 US US08/813,470 patent/US5866113A/en not_active Expired - Lifetime
- 1997-05-12 DE DE69718377T patent/DE69718377T2/en not_active Expired - Lifetime
- 1997-05-12 EP EP97303222A patent/EP0809997B1/en not_active Expired - Lifetime
- 1997-05-21 JP JP9130612A patent/JPH1052488A/en active Pending
- 1997-05-26 AU AU23619/97A patent/AU713357B2/en not_active Ceased
- 1997-05-26 CA CA002206147A patent/CA2206147A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5344455A (en) * | 1992-10-30 | 1994-09-06 | Medtronic, Inc. | Graft polymer articles having bioactive surfaces |
US5229172A (en) * | 1993-01-19 | 1993-07-20 | Medtronic, Inc. | Modification of polymeric surface by graft polymerization |
US5308641A (en) * | 1993-01-19 | 1994-05-03 | Medtronic, Inc. | Biocompatibility of solid surfaces |
US5350800A (en) * | 1993-01-19 | 1994-09-27 | Medtronic, Inc. | Method for improving the biocompatibility of solid surfaces |
US5415938A (en) * | 1993-01-19 | 1995-05-16 | Medtronic, Inc. | Biocompatability of solid surfaces |
Non-Patent Citations (20)
Title |
---|
A. Azeez et al., "In vitro Monocyte Adhesion and Activation on Modified FEP Copolymer Surfaces", J. Appl. Polym. Sci., 58, 1741-1749 (1995) (No month avail.). |
A. Azeez et al., In vitro Monocyte Adhesion and Activation on Modified FEP Copolymer Surfaces , J. Appl. Polym. Sci. , 58, 1741 1749 (1995) (No month avail.). * |
A.E. Potter Jr. et al., "The Vapor Phase Association of Acetic-d3, Acid-d",J. Phys. Chem., 59, 250-254 (1955) (No month avail.). |
A.E. Potter Jr. et al., The Vapor Phase Association of Acetic d 3 , Acid d , J. Phys. Chem. , 59, 250 254 (1955) (No month avail.). * |
F. Berthod et al., "Collagen synthesis by fibroblasts cultured within a collagen sponge", Biomaterials, 14, 749-754 (1993) (No month avail.). |
F. Berthod et al., Collagen synthesis by fibroblasts cultured within a collagen sponge , Biomaterials , 14, 749 754 (1993) (No month avail.). * |
H. Park et al., "Mechanisms of Mucoadhesion of Poly(acryic Acid) Hydrogels", Pharm. Res., 4, 457-464 (1987) (No month avail.). |
H. Park et al., Mechanisms of Mucoadhesion of Poly(acryic Acid) Hydrogels , Pharm. Res. , 4, 457 464 (1987) (No month avail.). * |
M. Akita et al., "Cell shape and arrangement of cultured aortic smooth muscle cells grown on collagen gels", Cell Tissue Res., 274, 91-95 (1993) (No month avail.). |
M. Akita et al., Cell shape and arrangement of cultured aortic smooth muscle cells grown on collagen gels , Cell Tissue Res. , 274, 91 95 (1993) (No month avail.). * |
T. Okada et al., "Surface Modification of Silicone for Tissue Adhesion", Biomaterials and Clinical Applications, Proceedings of the Sixth European Conference on Biomaterials, Bologna, Italy (Sep. 14-17, 1986), pp. 465-470. |
T. Okada et al., "Tissue reactions to subcutanteously implanted, surface-modified silicones", J. Biomed. Mat. Res., 27, 1509-1518 (1993) No month avail.). |
T. Okada et al., Surface Modification of Silicone for Tissue Adhesion , Biomaterials and Clinical Applications , Proceedings of the Sixth European Conference on Biomaterials, Bologna, Italy (Sep. 14 17, 1986), pp. 465 470. * |
T. Okada et al., Tissue reactions to subcutanteously implanted, surface modified silicones , J. Biomed. Mat. Res. , 27, 1509 1518 (1993) No month avail.). * |
Y. Kinoshita et al., "Soft tissue reaction to collagen-immobilized porous polyethylene: subcutaneous implantation in rats for 20 wk", Biomaterials, 14, 209-215 (1993) (No month avail.). |
Y. Kinoshita et al., Soft tissue reaction to collagen immobilized porous polyethylene: subcutaneous implantation in rats for 20 wk , Biomaterials , 14, 209 215 (1993) (No month avail.). * |
Y. Shimizu et al., "Studies on Composites of Collagen and a Synthetic Polymer", Biomat. Med., Dev., Art. Org., 375-391 (1978) (No month avail.). |
Y. Shimizu et al., "Studies on Copolymers of Collagen and a Synthetic Polymer", Biomat. Med., Dev., Art. Org., 5, 49-66 (1977) (No month avail.). |
Y. Shimizu et al., Studies on Composites of Collagen and a Synthetic Polymer , Biomat. Med., Dev., Art. Org. , 375 391 (1978) (No month avail.). * |
Y. Shimizu et al., Studies on Copolymers of Collagen and a Synthetic Polymer , Biomat. Med., Dev., Art. Org. , 5, 49 66 (1977) (No month avail.). * |
Cited By (208)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6010475A (en) * | 1996-09-19 | 2000-01-04 | Hospal Industrie | Apparatus for the treatment of blood by extracorporeal circulation and process of manufacture |
US6454998B1 (en) | 1996-09-19 | 2002-09-24 | Hospal Industrie | Blood circulation apparatus coupling device which improves biocompatibility of inner surfaces with treated blood |
US6248811B1 (en) * | 1997-01-03 | 2001-06-19 | Huels Aktiengesellschaft | Bioactive surface coating |
US6146771A (en) | 1997-07-01 | 2000-11-14 | Terumo Cardiovascular Systems Corporation | Process for modifying surfaces using the reaction product of a water-insoluble polymer and a polyalkylene imine |
US6093686A (en) * | 1998-03-12 | 2000-07-25 | Menicon Co., Ltd. | Liquid for contact lenses |
US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
US6830583B2 (en) | 1998-08-21 | 2004-12-14 | Medtronic Ave, Inc. | Thromboresistant coating composition |
USRE39438E1 (en) * | 1998-08-21 | 2006-12-19 | Medtronic Vascular, Inc. | Thromboresistant coated medical device |
US6361819B1 (en) | 1998-08-21 | 2002-03-26 | Medtronic Ave, Inc. | Thromboresistant coating method |
US6596401B1 (en) | 1998-11-10 | 2003-07-22 | C. R. Bard Inc. | Silane copolymer compositions containing active agents |
US6340465B1 (en) | 1999-04-12 | 2002-01-22 | Edwards Lifesciences Corp. | Lubricious coatings for medical devices |
US20020026235A1 (en) * | 1999-04-27 | 2002-02-28 | Sulzer Biologics, Inc. | Prosthetic grafts |
US20070086989A1 (en) * | 1999-04-27 | 2007-04-19 | Anderson Diane L | Prosthetic Grafts |
US6733747B2 (en) | 1999-04-27 | 2004-05-11 | Centerpulse Biologics Inc. | Prosthetic grafts |
US7147846B2 (en) | 1999-04-27 | 2006-12-12 | Zimmer Orthobiologics, Inc. | Prosthetic grafts |
US6328762B1 (en) | 1999-04-27 | 2001-12-11 | Sulzer Biologics, Inc. | Prosthetic grafts |
US20040235170A1 (en) * | 1999-04-27 | 2004-11-25 | Centerpulse Biologics Inc. | Prosthetic grafts |
US6309660B1 (en) | 1999-07-28 | 2001-10-30 | Edwards Lifesciences Corp. | Universal biocompatible coating platform for medical devices |
US6733513B2 (en) | 1999-11-04 | 2004-05-11 | Advanced Bioprosthetic Surfaces, Ltd. | Balloon catheter having metal balloon and method of making same |
US6936066B2 (en) | 1999-11-19 | 2005-08-30 | Advanced Bio Prosthetic Surfaces, Ltd. | Complaint implantable medical devices and methods of making same |
US7235092B2 (en) | 1999-11-19 | 2007-06-26 | Advanced Bio Prosthetic Surfaces, Ltd. | Guidewires and thin film catheter-sheaths and method of making same |
US10292849B2 (en) | 1999-11-19 | 2019-05-21 | Vactronix Scientific, Llc | Balloon catheter having metal balloon and method of making same |
US10172730B2 (en) | 1999-11-19 | 2019-01-08 | Vactronix Scientific, Llc | Stents with metallic covers and methods of making same |
US10106884B2 (en) * | 1999-11-19 | 2018-10-23 | Vactronix Scientific, Llc | Compliant implantable medical devices and methods of making same |
US8715335B2 (en) | 1999-11-19 | 2014-05-06 | Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. | Endoluminal implantable stent-grafts |
US6820676B2 (en) | 1999-11-19 | 2004-11-23 | Advanced Bio Prosthetic Surfaces, Ltd. | Endoluminal device exhibiting improved endothelialization and method of manufacture thereof |
US20130334032A1 (en) * | 1999-11-19 | 2013-12-19 | Advanced Bio Prosthetic Surfaces, Ltd. a wholly owned subsidiary of Palmaz Scientific, Inc. | Compliant implantable medical devices and methods of making same |
US6537310B1 (en) | 1999-11-19 | 2003-03-25 | Advanced Bio Prosthetic Surfaces, Ltd. | Endoluminal implantable devices and method of making same |
US10092390B2 (en) | 1999-11-19 | 2018-10-09 | Vactronix Scientific, Llc | Method of making implantable medical devices having controlled surface properties |
US6849085B2 (en) | 1999-11-19 | 2005-02-01 | Advanced Bio Prosthetic Surfaces, Ltd. | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and method of making same |
US9662230B2 (en) | 1999-11-19 | 2017-05-30 | Vactronix Scientific, Inc. | Implantable medical devices having controlled surface properties for improved healing response |
US8910363B2 (en) * | 1999-11-19 | 2014-12-16 | Advanced Bio Prosthetic Surfaces, Ltd. | Compliant implantable medical devices and methods of making same |
US10745799B2 (en) | 1999-11-19 | 2020-08-18 | Vactronix Scientific, Llc | Compliant implantable medical devices and methods of making same |
US10363125B2 (en) | 1999-11-19 | 2019-07-30 | Vactronix Scientific, Llc | Method of making implantable medical devices having controlled surface properties |
US20060015175A1 (en) * | 1999-11-19 | 2006-01-19 | Advanced Bio Prosthetic Surfaces, Ltd. | Compliant implantable medical devices and methods of making same |
US20030028246A1 (en) * | 1999-11-19 | 2003-02-06 | Palmaz Julio C. | Compliant implantable medical devices and methods of making same |
US20020165600A1 (en) * | 1999-11-19 | 2002-11-07 | Advanced Bio Prosthetic Surfaces, Ltd. | Guidewires and thin film catheter-sheaths and method of making same |
US9463305B2 (en) | 1999-11-19 | 2016-10-11 | Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. | Balloon catheter having metal balloon and method of making same |
US8460333B2 (en) | 1999-11-19 | 2013-06-11 | Advanced Bio Prosthetic Surfaces, Ltd. | Balloon catheter having metal balloon and method of making same |
US7195641B2 (en) | 1999-11-19 | 2007-03-27 | Advanced Bio Prosthetic Surfaces, Ltd. | Valvular prostheses having metal or pseudometallic construction and methods of manufacture |
US20150328025A1 (en) * | 1999-11-19 | 2015-11-19 | Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. | Compliant implantable medical devices and methods of making same |
US6379383B1 (en) | 1999-11-19 | 2002-04-30 | Advanced Bio Prosthetic Surfaces, Ltd. | Endoluminal device exhibiting improved endothelialization and method of manufacture thereof |
US9375330B2 (en) | 1999-11-19 | 2016-06-28 | Advanced Bio Prosthetic Surfaces, Ltd. | Methods of making medical devices |
US9284637B2 (en) | 1999-11-19 | 2016-03-15 | Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. | Implantable graft and methods of making same |
US7300457B2 (en) | 1999-11-19 | 2007-11-27 | Advanced Bio Prosthetic Surfaces, Ltd. | Self-supporting metallic implantable grafts, compliant implantable medical devices and methods of making same |
US20080027388A1 (en) * | 1999-11-19 | 2008-01-31 | Advanced Bio Prosthetic Surfaces, Ltd. | Guidewires and thin film catheter-sheaths and method of making same |
US9320626B2 (en) | 1999-11-19 | 2016-04-26 | Advanced Bio Prosthetic Surfaces, Ltd. | Guidewires and thin film catheter-sheaths and method of making same |
US7641680B2 (en) | 1999-11-19 | 2010-01-05 | Advanced Bio Prosthetic Surfaces, Ltd. | Endoluminal implantable stent-grafts |
US7491226B2 (en) | 1999-11-19 | 2009-02-17 | Advanced Bio Prosthetic Surfaces, Ltd. | Endoluminal implantable stent-grafts |
US7641682B2 (en) | 1999-11-19 | 2010-01-05 | Advanced Bio Prosthetic Surfaces, Ltd. | Compliant implantable medical devices and methods of making same |
US10874532B2 (en) | 1999-11-19 | 2020-12-29 | Vactronix Scientific, Llc | Implantable medical devices having controlled surface properties for improved healing response |
US6726718B1 (en) * | 1999-12-13 | 2004-04-27 | St. Jude Medical, Inc. | Medical articles prepared for cell adhesion |
US6579539B2 (en) | 1999-12-22 | 2003-06-17 | C. R. Bard, Inc. | Dual mode antimicrobial compositions |
US6695865B2 (en) | 2000-03-20 | 2004-02-24 | Advanced Bio Prosthetic Surfaces, Ltd. | Embolic protection device |
US6444217B1 (en) * | 2000-04-25 | 2002-09-03 | University Of Washington | Drug delivery devices, and methods of use |
US20050131521A1 (en) * | 2000-05-12 | 2005-06-16 | Denes Marton | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and methods of making same |
US20050165468A1 (en) * | 2000-05-12 | 2005-07-28 | Denes Marton | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and methods of making same |
US10939991B2 (en) | 2000-05-12 | 2021-03-09 | Vactronix Scientific, Llc | Monolithic biocompatible implantable laminated materials |
US8845713B2 (en) | 2000-05-12 | 2014-09-30 | Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and methods of making same |
US9566148B2 (en) | 2000-05-12 | 2017-02-14 | Vactronix Scientific, Inc. | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and methods of making same |
US10449030B2 (en) | 2000-05-12 | 2019-10-22 | Vactronix Scientific, Llc | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and methods of making same |
US10945828B2 (en) | 2000-05-12 | 2021-03-16 | Vactronix Scientific, Llc | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and methods of making same |
US10357354B2 (en) | 2000-05-12 | 2019-07-23 | Vactronix Scientific, Llc | Monolithic biocompatible implantable laminated materials |
US8641754B2 (en) | 2000-11-07 | 2014-02-04 | Advanced Bio Prosthetic Surfaces, Ltd. a wholly owned subsidiary of Palmaz Scientific, Inc. | Endoluminal stent, self-supporting endoluminal graft and methods of making same |
US8119184B2 (en) | 2001-04-12 | 2012-02-21 | Advanced Cardiovascular Systems, Inc. | Method of making a variable surface area stent |
US6764505B1 (en) | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
US7674493B2 (en) | 2001-04-12 | 2010-03-09 | Advanced Cardiovascular Systems, Inc. | Method of making a variable surface area stent |
US7862495B2 (en) | 2001-05-31 | 2011-01-04 | Advanced Cardiovascular Systems, Inc. | Radiation or drug delivery source with activity gradient to minimize edge effects |
US8025916B2 (en) | 2001-06-29 | 2011-09-27 | Abbott Cardiovascular Systems Inc. | Methods for forming a composite stent with regioselective material |
US8961584B2 (en) | 2001-06-29 | 2015-02-24 | Abbott Cardiovascular Systems Inc. | Composite stent with regioselective material |
US7169173B2 (en) | 2001-06-29 | 2007-01-30 | Advanced Cardiovascular Systems, Inc. | Composite stent with regioselective material and a method of forming the same |
US8458879B2 (en) | 2001-07-03 | 2013-06-11 | Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. | Method of fabricating an implantable medical device |
US7371258B2 (en) | 2001-10-26 | 2008-05-13 | St. Jude Medical, Inc. | Valved prosthesis with porous substrate |
US20030083741A1 (en) * | 2001-10-26 | 2003-05-01 | Yi-Ren Woo | Valved prosthesis with porous substrate |
US6837903B2 (en) * | 2002-03-22 | 2005-01-04 | Clemson University | Vascular biomaterial devices and methods |
WO2003082156A1 (en) * | 2002-03-22 | 2003-10-09 | Clemson University | Vascular biomaterial devices and methods |
US7992725B2 (en) | 2002-05-03 | 2011-08-09 | Biomet Biologics, Llc | Buoy suspension fractionation system |
US7837884B2 (en) | 2002-05-03 | 2010-11-23 | Hanuman, Llc | Methods and apparatus for isolating platelets from blood |
US8950586B2 (en) | 2002-05-03 | 2015-02-10 | Hanuman Llc | Methods and apparatus for isolating platelets from blood |
US8187477B2 (en) | 2002-05-03 | 2012-05-29 | Hanuman, Llc | Methods and apparatus for isolating platelets from blood |
US8062534B2 (en) | 2002-05-24 | 2011-11-22 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US10183042B2 (en) | 2002-05-24 | 2019-01-22 | Biomet Manufacturing, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US8808551B2 (en) | 2002-05-24 | 2014-08-19 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US7780860B2 (en) | 2002-05-24 | 2010-08-24 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US8603346B2 (en) | 2002-05-24 | 2013-12-10 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US8163184B2 (en) | 2002-05-24 | 2012-04-24 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US8048321B2 (en) | 2002-05-24 | 2011-11-01 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
US7845499B2 (en) | 2002-05-24 | 2010-12-07 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US9114334B2 (en) | 2002-05-24 | 2015-08-25 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US9897589B2 (en) | 2002-05-24 | 2018-02-20 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US10393728B2 (en) | 2002-05-24 | 2019-08-27 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US7914689B2 (en) | 2002-05-24 | 2011-03-29 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US7704274B2 (en) | 2002-09-26 | 2010-04-27 | Advanced Bio Prothestic Surfaces, Ltd. | Implantable graft and methods of making same |
US10465274B2 (en) | 2002-09-26 | 2019-11-05 | Vactronix Scientific, Llc | Implantable graft and methods of making same |
US7824441B2 (en) | 2002-11-12 | 2010-11-02 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
US7666223B2 (en) | 2002-11-12 | 2010-02-23 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
US7824440B2 (en) | 2002-11-12 | 2010-11-02 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
US7820229B2 (en) | 2002-11-12 | 2010-10-26 | Advanced Cardiovascular Systems, Inc. | Method of coating a stent |
US7169178B1 (en) | 2002-11-12 | 2007-01-30 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
US8197879B2 (en) | 2003-09-30 | 2012-06-12 | Advanced Cardiovascular Systems, Inc. | Method for selectively coating surfaces of a stent |
US20050147735A1 (en) * | 2003-12-23 | 2005-07-07 | Lowery Michael D. | Lubricious, biocompatible coatings for medical devices |
US8323799B2 (en) | 2005-04-11 | 2012-12-04 | Abbott Medical Optics Inc. | Medical devices having soft, flexible lubricious coatings |
US8053078B2 (en) | 2005-04-11 | 2011-11-08 | Abbott Medical Optics Inc. | Medical devices having soft, flexible lubricious coatings |
US20070075016A1 (en) * | 2005-08-23 | 2007-04-05 | Biomet Manufacturing Corp. | Method and apparatus for collecting biological materials |
US20070208321A1 (en) * | 2005-08-23 | 2007-09-06 | Biomet Manufacturing Corp. | Method And Apparatus For Collecting Biological Materials |
US8512575B2 (en) | 2005-08-23 | 2013-08-20 | Biomet Biologics, Llc | Method and apparatus for collecting biological materials |
US7771590B2 (en) | 2005-08-23 | 2010-08-10 | Biomet Manufacturing Corp. | Method and apparatus for collecting biological materials |
US8236258B2 (en) | 2005-08-23 | 2012-08-07 | Biomet Biologics, Llc | Method and apparatus for collecting biological materials |
US20100255977A1 (en) * | 2005-08-23 | 2010-10-07 | Biomet Manufacturing Corp. | Method and Apparatus for Collecting Biological Materials |
US8048320B2 (en) | 2005-08-23 | 2011-11-01 | Biomet Manufacturing Corp. | Method and apparatus for collecting biological materials |
US8048297B2 (en) | 2005-08-23 | 2011-11-01 | Biomet Biologics, Llc | Method and apparatus for collecting biological materials |
US8486483B2 (en) * | 2005-11-14 | 2013-07-16 | Biomet 3I, Llc | Deposition of discrete nanoparticles on an implant surface |
US9763751B2 (en) | 2005-11-14 | 2017-09-19 | Biomet 3I, Llc | Deposition of discrete nanoparticles on an implant surface |
US7771774B2 (en) | 2005-11-14 | 2010-08-10 | Biomet 3l, LLC | Deposition of discrete nanoparticles on an implant surface |
US7867547B2 (en) | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
US8647700B2 (en) | 2006-01-31 | 2014-02-11 | Advanced Bio Prosthetic Surfaces, Ltd. | Methods of making medical devices |
US7736687B2 (en) | 2006-01-31 | 2010-06-15 | Advance Bio Prosthetic Surfaces, Ltd. | Methods of making medical devices |
US8247020B2 (en) | 2006-01-31 | 2012-08-21 | Advanced Bio Prosthetic Surfaces, Ltd. | Methods of making medical devices |
US8003156B2 (en) | 2006-05-04 | 2011-08-23 | Advanced Cardiovascular Systems, Inc. | Rotatable support elements for stents |
US8637110B2 (en) | 2006-05-04 | 2014-01-28 | Advanced Cardiovascular Systems, Inc. | Rotatable support elements for stents |
US8596215B2 (en) | 2006-05-04 | 2013-12-03 | Advanced Cardiovascular Systems, Inc. | Rotatable support elements for stents |
US8741379B2 (en) | 2006-05-04 | 2014-06-03 | Advanced Cardiovascular Systems, Inc. | Rotatable support elements for stents |
US8465789B2 (en) | 2006-05-04 | 2013-06-18 | Advanced Cardiovascular Systems, Inc. | Rotatable support elements for stents |
US8567609B2 (en) | 2006-05-25 | 2013-10-29 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US8808342B2 (en) | 2006-06-14 | 2014-08-19 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
US8603530B2 (en) | 2006-06-14 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
US8048448B2 (en) | 2006-06-15 | 2011-11-01 | Abbott Cardiovascular Systems Inc. | Nanoshells for drug delivery |
US8592036B2 (en) | 2006-06-23 | 2013-11-26 | Abbott Cardiovascular Systems Inc. | Nanoshells on polymers |
US8017237B2 (en) | 2006-06-23 | 2011-09-13 | Abbott Cardiovascular Systems, Inc. | Nanoshells on polymers |
US8293367B2 (en) | 2006-06-23 | 2012-10-23 | Advanced Cardiovascular Systems, Inc. | Nanoshells on polymers |
US8114465B2 (en) | 2007-04-02 | 2012-02-14 | Ension, Inc. | Process for preparing a substrate coated with a biomolecule |
US10456227B2 (en) | 2007-04-02 | 2019-10-29 | Ension Inc. | Methods of surface treating tubular medical products |
US20080241349A1 (en) * | 2007-04-02 | 2008-10-02 | Ension, Inc. | Process for preparing a substrate coated with a biomolecule |
US9693841B2 (en) | 2007-04-02 | 2017-07-04 | Ension, Inc. | Surface treated staples, sutures and dental floss and methods of manufacturing the same |
US8343567B2 (en) | 2007-04-02 | 2013-01-01 | Ension, Inc. | Method of treating the surface of a medical device with a biomolecule |
US9649579B2 (en) | 2007-04-12 | 2017-05-16 | Hanuman Llc | Buoy suspension fractionation system |
US7806276B2 (en) | 2007-04-12 | 2010-10-05 | Hanuman, Llc | Buoy suspension fractionation system |
US9138664B2 (en) | 2007-04-12 | 2015-09-22 | Biomet Biologics, Llc | Buoy fractionation system |
US8596470B2 (en) | 2007-04-12 | 2013-12-03 | Hanuman, Llc | Buoy fractionation system |
US8119013B2 (en) | 2007-04-12 | 2012-02-21 | Hanuman, Llc | Method of separating a selected component from a multiple component material |
US8328024B2 (en) | 2007-04-12 | 2012-12-11 | Hanuman, Llc | Buoy suspension fractionation system |
US8048441B2 (en) | 2007-06-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Nanobead releasing medical devices |
WO2009046093A3 (en) * | 2007-10-01 | 2009-05-28 | Exogenesis Corp | Method and system for coating a surface of a medical device with a therapeutic agent and drug eluting medical devices made thereby |
US20090098186A1 (en) * | 2007-10-01 | 2009-04-16 | Exogenesis Corporation | Method and system for coating a surface of a medical device with a therapeutic agent and drug eluting medical devices made thereby |
US8282982B2 (en) * | 2007-10-01 | 2012-10-09 | Exogenesis Corporation | Method and system for coating a surface of a medical device with a therapeutic agent and drug eluting medical devices made thereby |
US8852672B2 (en) | 2008-01-28 | 2014-10-07 | Biomet 3I, Llc | Implant surface with increased hydrophilicity |
US9198742B2 (en) | 2008-01-28 | 2015-12-01 | Biomet 3I, Llc | Implant surface with increased hydrophilicity |
US8309162B2 (en) | 2008-01-28 | 2012-11-13 | Biomet 3I, Llc | Implant surface with increased hydrophilicity |
US11725031B2 (en) | 2008-02-27 | 2023-08-15 | Biomet Manufacturing, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
US10400017B2 (en) | 2008-02-27 | 2019-09-03 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
US9701728B2 (en) | 2008-02-27 | 2017-07-11 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
US8337711B2 (en) | 2008-02-29 | 2012-12-25 | Biomet Biologics, Llc | System and process for separating a material |
US8801586B2 (en) * | 2008-02-29 | 2014-08-12 | Biomet Biologics, Llc | System and process for separating a material |
US9719063B2 (en) | 2008-02-29 | 2017-08-01 | Biomet Biologics, Llc | System and process for separating a material |
US8783470B2 (en) | 2009-03-06 | 2014-07-22 | Biomet Biologics, Llc | Method and apparatus for producing autologous thrombin |
US8313954B2 (en) | 2009-04-03 | 2012-11-20 | Biomet Biologics, Llc | All-in-one means of separating blood components |
US8992862B2 (en) | 2009-04-03 | 2015-03-31 | Biomet Biologics, Llc | All-in-one means of separating blood components |
US9011800B2 (en) | 2009-07-16 | 2015-04-21 | Biomet Biologics, Llc | Method and apparatus for separating biological materials |
US9034201B2 (en) | 2010-03-29 | 2015-05-19 | Biomet 3I, Llc | Titanium nano-scale etching on an implant surface |
US8641418B2 (en) | 2010-03-29 | 2014-02-04 | Biomet 3I, Llc | Titanium nano-scale etching on an implant surface |
US9283056B2 (en) | 2010-03-29 | 2016-03-15 | Biomet 3I, Llc | Titanium nano-scale etching on an implant surface |
US10182887B2 (en) | 2010-03-29 | 2019-01-22 | Biomet 3I, Llc | Titanium nano-scale etching on an implant surface |
US10765494B2 (en) | 2010-03-29 | 2020-09-08 | Biomet 3I, Llc | Titanium nano-scale etching on an implant surface |
US9757212B2 (en) | 2010-03-29 | 2017-09-12 | Biomet 3I, Llc | Titanium nano-scale etching on an implant surface |
US8591391B2 (en) | 2010-04-12 | 2013-11-26 | Biomet Biologics, Llc | Method and apparatus for separating a material |
US9533090B2 (en) | 2010-04-12 | 2017-01-03 | Biomet Biologics, Llc | Method and apparatus for separating a material |
US9816009B2 (en) | 2010-07-30 | 2017-11-14 | Novartis Ag | Silicone hydrogel lenses with water-rich surfaces |
US9738813B2 (en) | 2010-07-30 | 2017-08-22 | Novartis Ag | Silicone hydrogel lens with a crosslinked hydrophilic coating |
US9411171B2 (en) | 2010-07-30 | 2016-08-09 | Novartis Ag | Silicone hydrogel lenses with water-rich surfaces |
US8529057B2 (en) | 2010-07-30 | 2013-09-10 | Novartis Ag | Silicone hydrogel lens with a crosslinked hydrophilic coating |
US9507173B2 (en) | 2010-07-30 | 2016-11-29 | Novartis Ag | Silicone hydrogel lens with a crosslinked hydrophilic coating |
US9239409B2 (en) | 2010-07-30 | 2016-01-19 | Novartis Ag | Silicone hydrogel lens with a crosslinked hydrophilic coating |
US8480227B2 (en) | 2010-07-30 | 2013-07-09 | Novartis Ag | Silicone hydrogel lenses with water-rich surfaces |
US8939577B2 (en) | 2010-07-30 | 2015-01-27 | Novartis Ag | Silicone hydrogel lenses with water-rich surfaces |
US10781340B2 (en) | 2010-07-30 | 2020-09-22 | Alcon Inc. | Silicone hydrogel lenses with water-rich surfaces |
US9244200B2 (en) | 2010-07-30 | 2016-01-26 | Novartis Ag | Silicone hydrogel lenses with water-rich surfaces |
US8944592B2 (en) | 2010-07-30 | 2015-02-03 | Novartis Ag | Silicone hydrogel lens with a crosslinked hydrophilic coating |
WO2012088045A1 (en) | 2010-12-23 | 2012-06-28 | Medtronic, Inc. | Medical electrical lead having biological surface and methods of making and using same |
US9861814B2 (en) | 2010-12-23 | 2018-01-09 | Medtronic, Inc. | Medical electrical lead having biological surface and methods of making and using same |
US9239276B2 (en) | 2011-04-19 | 2016-01-19 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US9005700B2 (en) | 2011-10-12 | 2015-04-14 | Novartis Ag | Method for making UV-absorbing ophthalmic lenses |
US9131995B2 (en) | 2012-03-20 | 2015-09-15 | Biomet 3I, Llc | Surface treatment for an implant surface |
US9642956B2 (en) | 2012-08-27 | 2017-05-09 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US9737905B2 (en) | 2012-08-29 | 2017-08-22 | Cardiac Pacemakers, Inc. | Enhanced low friction coating for medical leads and methods of making |
US9180289B2 (en) | 2012-08-29 | 2015-11-10 | Cardiac Pacemakers, Inc. | Enhanced low friction coating for medical leads and methods of making |
US9119956B2 (en) | 2012-11-21 | 2015-09-01 | Cardiac Pacemakers, Inc. | Medical electrodes with layered coatings |
US10338408B2 (en) | 2012-12-17 | 2019-07-02 | Novartis Ag | Method for making improved UV-absorbing ophthalmic lenses |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US10441634B2 (en) | 2013-03-15 | 2019-10-15 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US10576130B2 (en) | 2013-03-15 | 2020-03-03 | Biomet Manufacturing, Llc | Treatment of collagen defects using protein solutions |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US9556243B2 (en) | 2013-03-15 | 2017-01-31 | Biomet Biologies, LLC | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
WO2015009431A1 (en) * | 2013-07-19 | 2015-01-22 | Rarecyte, Inc. | Solution and method for adhering suspension components to a substrate |
US9708087B2 (en) | 2013-12-17 | 2017-07-18 | Novartis Ag | Silicone hydrogel lens with a crosslinked hydrophilic coating |
US11002884B2 (en) | 2014-08-26 | 2021-05-11 | Alcon Inc. | Method for applying stable coating on silicone hydrogel contact lenses |
WO2016089966A1 (en) * | 2014-12-02 | 2016-06-09 | Rarecyte, Inc. | Solution and method for adhering suspension components to a substrate |
US10709822B2 (en) * | 2015-03-31 | 2020-07-14 | Toray Industries, Inc. | Antithrombotic metallic material |
US20180344906A1 (en) * | 2015-03-31 | 2018-12-06 | Toray Industries, Inc. | Antithrombotic metallic material |
US10449740B2 (en) | 2015-12-15 | 2019-10-22 | Novartis Ag | Method for applying stable coating on silicone hydrogel contact lenses |
US10830923B2 (en) | 2017-12-13 | 2020-11-10 | Alcon Inc. | Method for producing MPS-compatible water gradient contact lenses |
US11029447B2 (en) | 2017-12-13 | 2021-06-08 | Alcon Inc. | Method for producing MPS-compatible water gradient contact lenses |
US11029446B2 (en) | 2017-12-13 | 2021-06-08 | Alcon Inc. | Method for producing MPS-compatible water gradient contact lenses |
US11256003B2 (en) | 2017-12-13 | 2022-02-22 | Alcon Inc. | Weekly and monthly disposable water gradient contact lenses |
US20210369923A1 (en) * | 2020-05-26 | 2021-12-02 | Sichuan University | Recombinant human collagen-based multifunctional stent coating and preparation method thereof |
US11844880B2 (en) * | 2020-05-26 | 2023-12-19 | Sichuan University | Recombinant human collagen-based multifunctional stent coating and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2361997A (en) | 1997-12-04 |
EP0809997A3 (en) | 1999-12-22 |
JPH1052488A (en) | 1998-02-24 |
CA2206147A1 (en) | 1997-11-30 |
DE69718377T2 (en) | 2003-10-23 |
AU713357B2 (en) | 1999-12-02 |
EP0809997A2 (en) | 1997-12-03 |
EP0809997B1 (en) | 2003-01-15 |
US5866113A (en) | 1999-02-02 |
DE69718377D1 (en) | 2003-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5811151A (en) | Method of modifying the surface of a medical device | |
US5821343A (en) | Oxidative method for attachment of biomolecules to surfaces of medical devices | |
US5728420A (en) | Oxidative method for attachment of glycoproteins to surfaces of medical devices | |
US5945319A (en) | Periodate oxidative method for attachment of biomolecules to medical device surfaces | |
JP2691854B2 (en) | A method for providing a bioactive surface to an article having a bioactive surface, an antithrombotic and infection resistant article, and a subcutaneously implantable article. | |
US5891506A (en) | Oxidative method for attachment of glycoproteins or glycopeptides to surfaces of medical devices | |
US5415938A (en) | Biocompatability of solid surfaces | |
US6143354A (en) | One-step method for attachment of biomolecules to substrate surfaces | |
US5607475A (en) | Biocompatible medical article and method | |
US5925552A (en) | Method for attachment of biomolecules to medical devices surfaces | |
US20020120333A1 (en) | Method for coating medical device surfaces | |
JP3694322B2 (en) | Biocompatible medical products and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MEDTRONIC, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HENDRIKS, MARC;CAHALAN, LINDA L.;CAHALAN, PATRICK T.;AND OTHERS;REEL/FRAME:008092/0044 Effective date: 19960709 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |